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ABSTRACT

An abstract of the dissertation of Casey Lee Quinlan for the Doctor of
Philosophy in Biology, presented September 26, 2008.

Title: Cardioprotective Signal Transduction to Mitochondria

Intracellular responses to external stimuli require reception of the
message at the plasma membrane followed by encoding and transmission
of the message to its effectors downstream. In this process, diverse cellular
responses are mediated by many redundant molecular players. The
apparent generality and redundancy of many kinases, such as the mitogenactivated protein kinases (MAPKs), suggests that signal transduction must
gain specificity through tight regulation. Diffusion and random collisions of
relevant signaling components seem insufficient to explain the multilayered
complexity observed in cell signaling cascades. Emerging hypotheses
suggest that signaling machinery may achieve enhanced specificity and
control by exploiting the compartmentalization capabilities of plasma
membrane microdomains. This study examines the hypothesis that
treatment of the heart with the cardioprotective agents, ouabain or
bradykinin, instigates formation of a signaling platform (or signalosome) that
encompasses all the enzymes of the receptor-mediated pathway. The
signalosome serves to compartmentalize and deliver the signaling

components to mitochondria where it facilitates opening of the mitochondrial
ATP-sensitive K+channel and instigation of an intramitochondrial signaling
pathway that mediates cardioprotection.
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1. introduction

1.1 Cardioprotection and Mitochondria
Heart attacks and their associated ischemic events are together a major
cause of death in the United States and world wide. According to the
American Heart Association, there are 1.2 million new and recurrent coronary
attacks per year, and of these about 38 percent result in death (191).
Investigations into the damage-causing mechanisms of a heart attack have
revealed that both apoptotic and necrotic cell death pathways are triggered
downstream of the coronary thrombosis, and this cell death is at the root of the
observed injury (52, 223). Necrotic and apoptotic cell death pathways are
distinct in many respects, but both have been shown to involve mitochondria
(37, 77, 90, 126). In this regard, many agents that affect mitochondria have
been shown to reduce ischemic damage; treatments that reduce such injury
are referred to as cardioprotective.
The 1986 discovery of the phenomenon known as ischemic
preconditioning (IPC), whereby cardioprotection is achieved through brief
cycles of ischemia and reperfusion prior to a significant ischemic event, has
spurred significant interest in the mechanisms of protection from cardiac injury
(148). Since the discovery of IPC, many drugs have been shown to mimic its
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effects, including a number of G-coupled receptor agonists, agents that target
specific kinases, and (of particular interest to this study) activation of the
mitochondrial ATP-sensitive K+ channel (mitoKATP)(50, 71). These disparate
treatments all hold in common their ability to affect mitochondria and limit
necrotic and apoptotic cell death pathways.
Mitochondria are well characterized as the ubiquitous organelles of
aerobic metabolism. Beyond this definition, their role can be expanded to
include critical importance in the processes of reactive oxygen species (ROS)
production, intracellular signaling pathways and, as mentioned above,
apoptotic/necrotic death pathways (5, 6, 50, 108, 146). All known
cardioprotective pathways inhibit cellular necrosis, which itself is a direct
manifestation of the mitochondrial permeability transition (MPT). MPT is a
large-conductance pore that allows the passage of solutes of up to 1500 Da.
The occurrence of this pathology results in the loss of mitochondrial membrane
integrity and membrane potential, which in turn compromises ATP production
(40). The exact molecular identity of MPT is unknown; it is hypothesized to be
a multiprotein pore composed of such prevalent membrane proteins as the
adenine nucleotide translocase (ANT) and voltage-dependent anion channel
(VDAC), but the only proven pore component is cyclophilin D (10).
Cyclosporin A, the best known pharmacologic inhibitor of MPT, binds to
cyclophilin D (39). Activation of the mitoKATP channel has been shown to
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inhibit pathological manifestations of MPT (32).
The mitoKATP channel was simultaneously discovered by two labs in
1991. Patch clamp studies and reconstitution assays both found evidence for
the presence of a potassium uniport pathway in the mitochondrial inner
membrane (84, 91). In the years that have followed, work in our laboratory has
focused on the role that mitoKATP plays in cellular physiology and pathology.
We, and others, have found that mitoKATP is a receptor for cardioprotective
potassium-channel openers (64, 71, 72, 82). We have shown that opening
mitoKATP is cardioprotective through a mechanism involving mitochondrial
ROS production and inhibition of cellular necrosis (4, 32). In Chapter 2, an
analysis of the direct physiological effects of mitoKATP-opening is discussed.
As stated above, all methods of cardioprotection protect the
mitochondria from the pathological occurrence of MPT. In this respect, MPT
could be considered the "end-effector" of cardioprotection; triggers of this endeffect are numerous. IPC, the gold standard of cardioprotection, generates
several cardioprotective G-protein coupled receptor (GPCR) agonists such as
adenosine, opioids, and bradykinin. When bound to their receptors these
compounds instigate activation of a number of downstream targets, such as
Akt, protein kinase C (PKC), nitric oxide synthase (NOS), protein kinase G
(PKG), and activation of mitoKATP (12, 26, 79, 146, 224, 232, 239).
MitoKATP activation is known to be a crucial component of
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cardioprotection. Its inhibition blocks all known forms of cardioprotection (82,
88). Opening of mitoKATP, either directly by pharmacological means or by
activation of upstream signaling pathways, leads to the instigation of the
intramitochondrial signaling pathway which involves multiple steps and will be
detailed in the following section.
1.2 Intramitochondrial signaling
The diagram in Fig. 1.1 summarizes several years of studies on
intramitochondrial signaling (4, 31, 32, 34, 35, 62, 93, 186). The primary
function of this pathway is to inhibit MPT opening, which is widely considered
to be the cause of cell death after ischemia-reperfusion (7, 38, 45).
Step one - opening mitaKATP
Direct mitoKATP opening by KATP channel openers (KCO)
The ability of KCOs to open mitoKATP in their therapeutic dose range
was described in 1996 (72). KCOs act on the regulatory sulfonylurea
receptors (SUR) of KATP channels. Pinacidil, cromakalim, and nicorandil are
effective openers of cardiac KATP through their action on SUR2A, but
ineffective on the pancreatic beta cell KATP, which uses SUR1. Conversely,
diazoxide is an effective opener of beta cell KATP, but ineffective on the cardiac
channel (145). All KCOs we have examined, including those listed above,
open mitoKATP and protect the heart from ischemia-reperfusion injury (35, 71,
72,81,94,115,162,185).
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Figure 1.1 The intramitochondrial signaling pathways. The pathways
leading to mitoKATP opening, ROS production, and MPT inhibition are shown.
Positive and negative regulation of pathway components is indicated by plus
(+) and minus (-) symbols, respectively. MitoKATP is opened by activation of
PKG, and stimulation of PKCsl. MPT is inhibited by the mitoKATP-induced
ROS activation of PKCs2, or exogenous addition of activators such PMA.
Please see the text for a complete description. This figure has been modified
from Costa and Garlid (34).

Figure 1.1
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Indirect mitoKATP opening, by signaling to PKCsl
Ischemic preconditioning, ischemic postconditioning, and
pharmacological preconditioning via plasma membrane receptor agonists
cause mitoKATP opening by activating a signaling pathway that signals to a
constitutive mitochondrial Protein kinase C epsilon, PKCs. Our studies
suggest that this PKCs lies directly upstream of mitoKATP (32, 34, 93). The
PKCs-specific peptide agonist UJsRACK and the general PKCs agonists
H202, NO, and phorbol 12-myristate 13-acetate (PMA) each open mitoKATP
(34).(190). That these agents were acting via PKCs ("PKCsl" in Fig. 1.1) was
verified by showing that the PKCs-specific binding antagonist sV.,.2 blocked all
four modes of PKCs activation of mitoKATP, but did not block pharmacological
mitoKATP opening by diazoxide (34, 93). Moreover, the PKC inhibitor
G66983, which inhibits the PKC isoforms PKCa, PKCp, PKCy, and PKC^,
did not block PKCs-dependent mitoKATP opening, excluding a role for these
isoforms (31).
PKCs requires anionic phospholipids for activity and is activated
physiologically by diacylglycerol (or phorbol ester) or by a sulfydryl oxidizing
agent, such as H 2 0 2 (212) or NO (34). PMA or H 2 0 2 opens up one of the two
zinc fingers in PKCs (104, 113). In mitochondria, the phospholipid
requirement is met by cardiolipin, which is abundant. MJsRACK, PMA, H 2 0 2 ,
or NO cause conformational changes that expose the substrate domain on
6

PKCs, allowing for the active conformation of the enzyme (190). M^sRACK is
a PKCs-specific peptide agonist that acts by regulating intramolecular PKCs
binding, and s V ^ is a PKCs-specific peptide antagonist that acts by
preventing protein-protein interactions between PKCs and its binding protein
(97, 190, 210). PKCs has been shown to be crucial for cardioprotection in a
number of models (11, 58, 198).The specific activators and inhibitors of PKCs
have been shown to modulate cardioprotection in both isolated
cardiomyocytes as well as perfused heart studies (147).
Jaburek, et al. (93) showed in reconstituted liposomes that the PKCs
agonist <4JsRACK opens, and the antagonist e\Zu2 closes, the partially in
reconstituted liposomes. This, together with the finding that PKCs remains
associated with mitochondria in mitoplasts (32), raises the possibility that
PKCs and mitoKATP are part of a functional complex. In studies performed in
mitoplasts, mitochondria lacking their outer membrane, the protein
phosphatase PP2A prevents mitoKATP-dependent swelling induced by PKCs
agonists (34), and we conclude that PKCs-dependent mitoKATP opening
requires inner membrane phosphorylation, perhaps of mitoKATP itself.

Step two - mitochondrial fC uptake and its consequences
7

Once mitoKATP is opened, the increase in K+ uptake leads to several
changes in the matrix. Electrophoretic K+ influx is balanced by electrogenic H+
efflux driven by the respiratory chain. Uncompensated, this would cause an
increase of matrix pH by about 2 pH units (4). Partial compensation is
provided by electroneutral uptake of substrate anions, such as phosphate. The
compensation is partial because the concentration of phosphate in the cytosol
is much lower than that of K+, and this imbalance leads to matrix alkalinization
(4, 35, 70).
Matrix alkalinization now releases the K7H+ antiporter from inhibition by
matrix protons (17), causing K+ efflux to increase in response to increased K+
uptake until a new K+ steady state is achieved. The uncoupling caused by
increased futile cycling of K+ is about 3% of the maximum activity of the
electron transport chain. This low level of uncoupling reflects the low activity of
mitoKATP, a property that is essential for mitochondrial survival. Thus, if we
add sufficient amounts of the K+ ionophore valinomycin to double the
electrophoretic K+ influx, the MOM will rupture with loss of cytochrome c and
respiratory inhibition (35). This is an important point, mitoKATP catalyzes
sufficiently low K+ conductance that membrane integrity is not compromised by
its activity.
Uptake of K+ salts and osmotically obligated water leads to increased
matrix volume ("AV" in Fig. 1.1), which is the basis of the light scattering (LS)
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assay for mitoKATP activity (35). LS is the only practical method to study this
process in isolated mitochondria, because mitoKATP-dependent K+ flux is
rapid (t1/2 ~ 30 s) and, as stated above, minimal. This technique has been
successfully employed by several laboratories to measure K+ flux in
mitochondria (54, 174, 189, 192, 233).
MitoKATP-dependent matrix alkalinization plays an essential role in
intramitochondrial signaling. It causes a slight reduction in the rate of electron
transport and concomitant increase in ROS production at Complex I (4). As
seen below, the ROS produced by this mechanism play two important roles in
cardioprotection, through their ability to activate

PKCE.

We note that each of the consequences of mitoKATP opening are due
specifically to the increased K+ influx. Thus, when mitoKATP is inhibited, the K+
ionophore valinomycin (approximately 1 pmol/mg mitochondria) duplicates the
effects of the channel in terms of K+ uptake, respiration, matrix alkalinization,
volume increase, and ROS production (4, 35).

Step three - activation of PKCe by endogenous ROS
ROS activation of PKCs2 and inhibition of MPT.
The increased ROS activates a second mitochondrial PKCs, "PKCs2"
in Fig. 1.1, which inhibits the mitochondrial permeability transition ("MPT") in a
phosphorylation-dependent reaction (32). The evidence for two distinct
9

mitochondrial PKCs, one acting on mitoKATP and the other on MPT, is as
follows: (1) PMA or H 2 0 2 opens mitoKATP and inhibits MPT.

EV-,.2

blocks both

of these effects of PMA or H202, indicating that the effects are due to PKCs
activation. However, glibenclamide or 5-HD blocks only mitoKATP opening and
has no effect on MPT inhibition. This indicates that PKCs2 can inhibit MPT
directly, without the intervention of mitoKATP (32). H 2 0 2 and NO, but not
superoxide, also activate PKCs2 and inhibit MPT (32, 34). The dichotomy
between protective and damaging ROS was strikingly demonstrated in a
series of experiments to assay MPT. MPT is induced in vitro and in vivo under
conditions of high ROS (damaging, 100 p,M H202). Interestingly, conditioning
the mitochondria with a low amount of ROS (2 \iM H202) 1 min prior to
administering the damaging ROS will inhibit the onset of MPT (32). This same
effect has been observed in the isolated perfused heart as well. Hearts have
been shown to be protected from a lethal ischemic event by preconditioning
with 2 |aM H202 (237). Thus, the redundant modes of cardioprotective
mitoKATP opening described above lead to inhibition of MPT, and, therefore,
to reduction of cell death after ischemia-reperfusion injury (7, 38, 45).

ROS activation ofPKCsl and feedback mitoKATP opening.
The mitoKATP-dependent increase in ROS plays an additional role in
cardioprotection. Note in Fig. 1.1 that PKCel is bypassed when KCOs are
10

administered to the heart; however, we have found that PKCsl is soon
activated by mitoKATP-dependent ROS, leading to a persistent
phosphorylation-dependent open state of mitoKATP (34). These data define a
new, positive feedback loop for mitoKATP opening, whose existence, which has
been suggested by a number of authors (101, 106, 124), means that mitoKATP
may be either upstream or downstream of PKCe, depending on the triggering
stimulus. We suggest that feedback phosphorylation of mitoKATP is the
mechanism of memory, which is seen with all PC triggers (49, 165). Thus,
cardioprotective stimuli can be washed away from the system and the
perfused heart remains protected from a major ischemic assault, thanks to
phosphorylation of mitoKATP. We infer, but have not demonstrated, that
mitoKATP opening is eventually reversed by an endogenous phosphatase
("PP2A" in Fig. 1.1) within the intermembrane space. For example, PP2A has
been found in mitochondria where it is activated by proapoptotic factors (111).

Support for the intramitochondrial signaling model
The model in Fig. 1.1 helps to support and extend results of previous
studies. Jiang et al (96) observed PKC and 5-HD regulation of the human
cardiac mitoKATP in lipid bilayers. Garg and Hu (61) showed that PKCs
modulates mitoKATP activity in cardiomyocytes and COS-7 cells. Penna et al
11

(177) demonstrated that protection by postconditioning protection involves a
redox mechanism and persistent activation of mitoKATP and PKC. Facundo et
al. (54) showed that H 2 0 2 induces mitoKATP activity in isolated mitochondria,
but did not identify participation of PKCe. Zhang et al. (244) found that
superoxide anion activated mitoKATP in planar bilayers, and we showed that
this effect is mediated, not by superoxide, but by H 2 0 2 acting indirectly via
PKCsl (34). Sasaki, et al. (197) suggested that NO may open mitoKATP
directly; however mitoKATP opening by NO is blocked by s V ^ (34), showing
that NO opens mitoKATP indirectly through PKCsl Several authors have
shown that exogenous and endogenous NO are cardioprotective and have
attributed this effect to MPT inhibition (24, 99, 109, 227). Brookes, et al. (24)
showed that NO inhibited MPT and cytochrome c release in isolated liver
mitochondria. We showed that this effect is independent of mitoKATP activity
and occurs via activation of PKCs2 (34). Korge, et al. (112) found that
diazoxide prevented MPT opening and cytochrome c loss, and that both
effects were mimicked by the PKC activator PMA and blocked by 5-HD. Kim,
et al. (110) found that a cytosolic extract, together with cGMP and ATP,
blocked MPT in isolated mitochondria, an effect that was blocked by PKG
inhibition. Forbes, et al (56) and Pain, et al (165) found that N-acetylcysteine
or MPG reversed the protective effect of diazoxide in perfused hearts. Our
data suggests that blockade of protection occurred because mitoKATP12

dependent ROS was scavenged and unavailable to activate PKCs2 and
inhibit MPT. Lebuffe, et al (124) found that PMA-induced protection was
blocked by 5-HD and that this block was reversed by coadministration of H 2 0 2
and NO. This is also consistent with the model of Fig. 1.1 in that H 2 0 2 and NO
can bypass the blocked mitoKATP and act directly on PKCs2, thereby inhibiting
MPT and protecting the heart.
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1.3 Study compounds: Bradykinin and Ouabain
This study examines the cardioprotective profiles of two compounds,
ouabain and bradykinin. The rational behind the selection of these two agents
is that they activate distinct cardioprotective pathways that converge on
mitoKATP-opening. The pharmacological differences between these
compounds as well as their cardioprotective profile will be discussed.

Figure 1.2
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Figure 1.2 Study compounds: Bradykinin and Ouabain. A pictorial
representation of the two drugs used in this study. Bradykinin, a 9-amino acid
peptide, and ouabain a steroidal compound.

Bradykinin
Bradykinin is one of a number of short biologically active peptides
called kinins. Since its discovery in 1949, many physiological and pathological
manifestations of bradykinin have been investigated (100, 176) In the
14

cardiovascular system, bradykinin is a classic vasodilator mediated by the
release of nitric oxide and prostacylin (176). Interestingly, several actions of
bradykinin in the heart are independent of its action as vasodilator/ peptide.
The precursor to bradykinin is circulating kininogen released from the
liver. Bradykinin is produced from the proteolytic cleavage of kininogen by
kallikrein, a serine protease (25, 176). In plasma, activation of kallikrein is a
feature of the intrinsic clotting cascade, the first step of which is the activation
of factor XII (Hageman factor). This is by far the more complex pathway and
not presumed to be the pathway in most tissues. Vascular endothelial cells
are the primary source of bradykinin in the heart. In this case, enzymatic
cleavage of pre-kallikrein generates kallikrein at the endothelial cell surface,
which then cleaves kinongens to produce bradykinin (176).
Bradykinin binds to two cell surface GPCRs in cardiomyocytes, the
constitutively expressed B2 and the stress induced B1 (76). The B2 receptor
is of the greatest interest here as it is known to mediate the effects of
cardioprotection (79, 114, 161, 238, 239). Bradykinin, administered at a dose
below that which induces coronary vasodilation, instigates a cellular signaling
pathway that has been well described in the literature (160). Interaction of
bradykinin with its receptor causes activation of phosphatidylinositol 3-kinase
(PI3K), which phosphorylates membrane phospholipids to yield
phosphatidylinositol trisphosphate, which then activates phospholipid
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dependent kinases (PDK), which in turn causes phosphorylation and activation
of Akt. Akt phosphorylates endothelial nitric oxide synthase (eNOS), causing it
to increase generation of NO. NO activates soluble guanylyl cyclase (GC),
causing it to synthesize cGMP which then activates protein kinase G (PKG).
PKG acts on the mitochondrial outer membrane (MOM), causing opening of
inner membrane mitoKATP channels (31) and inhibition of MPT (32). As in all
signaling pathways, there are multiple enzymes interacting in complex ways to
mediate the end effect. In chapter 4 of this text, I investigate the hypothesis that
this signaling complexity and specificity is attained by means of
compartmentalization of bradykinin pathway components.
Ouabain
Cardiac glycosides, such as digitalis and ouabain, have been used in
the treatment of congestive heart failure for at least 200 years (125). Ouabain,
a water-soluble cardiotonic steroid derived from the Ouabaio tree, acts as a
specific inhibitor of the N+,K+-ATPase in the plasma membrane. Its binding to
and inhibition of the N+,K+-ATPase generates a condition of increased
contractility in the heart referred to as positive inotropy. It is suggested that the
positive inotropic response is due to the increased intracellular Na+
concentrations that occur when the N+,K+-ATPase is inhibited. The Na+
increase activates the Na7Ca2+ exchanger leading to increased intracellular
Ca2+ (204), and Ca2+ is integral to the contractile response of muscle tissue.
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Since its discovery in 1957, the N+,K+-ATPase has been well described
as the "sodium pump" responsible for the formation and maintenance of the
plasma membrane ionic gradient and membrane potential (213). Also in the
ensuing decades it has become clear that the N+,K+-ATPase performs
functions that are distinct from its role as an ion pump. For example, it has
been known for some time that the N+,K+-ATPase is capable of modulating its
own gene expression and the expression of genes involved in cell growth (150,
158), suggesting a signaling capacity of the enzyme. Interestingly, the same
nontoxic concentrations of ouabain that induce a positive inotropic response
have also been linked to nonproliferative cell growth (hypertrophy) in the heart
(234). This suggests an inducible change in gene expression and an
interesting model for examining heart failure. The work of Xie, Askari, and
colleagues has contributed much to this field. They have found that the
instigation of hypertrophy is through signal transduction pathways that originate
at the N+,K+-ATPase and induce a number of early response proto-oncogenes,
activate transcription factors activator protein-1 (AP-1) and

NF-KB,

and induce

or repress the transcription of several cardiac marker genes known to be
involved in the hypertrophic response (144, 235). Ouabain, when used to
precondition the heart, has been shown to initiate the formation of a signaling
module between N+,K+-ATPase, Src, and PKCs that mediates the
cardioprotective effect. It is within the capacity as a signal transducing
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receptor that the N+,K+-ATPase and its ligand ouabain will be discussed here.
In Chapter 3 of this text, ouabain's cardioprotective profile is examined
in the isolated heart and skinned cardiac fiber models. Preconditioning with
ouabain was found to reduce infarction, protect heart function, and preserve
adenine nucleotide compartmentation in mitochondria. We compared
ouabain cardioprotection with bradykinin and found, through the use of
inhibitors, that both pathways depend on src kinase, mitoKATP, and ROS. We
also show that the ouabain pathway does not utilize PKG, which is surprising
because most known forms of cardioprotection seem to be mediated by PKG.
In Chapter 5, the ouabain mechanism of cardioprotection is further
explored. This study examines the hypothesis that ouabain binding to the
N+,K+-ATPase instigates the formation of a signaling platform that recruits the
enzymes of the cascade into a signalosome that mediates opening of the
mitoKATP channel. It is shown that the terminal kinases upstream of
mitochondria are Src and PKCs, and that these phosphorylate and activate
p38 MAPK located in mitochondria.
1.4 Compartmentalization of Signaling Components
The vast majority of signaling accomplished by hormones and
neurotransmitters in the cardiovascular system is exerted through G-protein
coupled receptors (GPCRs), which are receptors with the characteristic 7transmembrane domain morphology. Agonist stimulation causes
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conformational change of the receptor and association with heterotrimeric Gproteins within the plasma membrane. This interaction causes binding of GTP
to the Ga subunit, followed by disassociation of the Gpy subunit, and
ultimately regulation of various effectors such as enzymes or ion channels
(179). Despite the redundancy of many of the enzymes in these pathways,
impressive specificity is observed in GPCR signaling.
Much of the research on signaling pathways has focused on identifying
the linear progression of pathway components. This approach has yielded
crucial information regarding the G-proteins involved in pathways and their
cognate downstream effectors. In this light, the current dogma suggests that
this linear "bucket brigade" means of signal transduction gains specificity by
diffusion and high-affinity protein-protein interactions. However, many GPCRs
appear to elicit diverse cellular effects through coupling to the same the Gprotein or by activating seemingly redundant pathways (163). The inability of
this simple explanation to account for the observed complexity in signaling has
prompted.many investigators to propose enhanced spacial and temporal
levels of control, such as membrane scaffolding and new roles for endocytosis
(107, 135, 175,203).
The hypothesis that membrane microdomains may act as signaling
scaffolds is not a new one per se; the concentration of G-protein coupled
GPCRs in so-called lipid rafts, subdomains enriched in cholesterol and
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glycosphingolipids, is well supported in the literature, i.e. the andrenergic,
angiotensin, and bradykinin receptors have all been found enriched in lipid
rafts or caveolae (19, 122). Interestingly, the Na+,K+-ATPase is known to
associate with caveolar microdomains as well (131). The membrane
microdomains, caveolae, are often discussed interchangeably with lipid rafts
because of their similar biochemical properties (28, 57, 170). Caveolae,
however, are morphologically distinct 50-100 nm "flask-like" membrane
invaginations which contain the integral membrane protein caveolin. Caveolin
exists in three isoforms: Caveolin-1 and -2 are expressed in a variety of cell
types including endothelial, epithelial, and fibroblasts; whereas caveolin-3
appears to be muscle-tissue specific (51, 116, 167, 200). Lipid rafts/caveolae
are often described biochemically by their well defined buoyancy in density
gradients and resistance to nonionic detergents like Triton-X 100 (3, 206).
Caveolae have been shown to be involved in endocytic events on a broad
scale. They have been implicated in the internalization of macromolecules
such as albumin, and have been suggested to modulate receptor
desensitization in a complimentary pathway to clathrin-coated pits (41, 171,
194).
The interesting biochemical properties of caveolae as well as their
ability to sequester and regulate signaling molecules has brought them to the
forefront of many signaling hypotheses. Caveolins have been shown to
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intimately regulate signaling pathway components, in particular those
molecules with lipid-modified groups such as heterotrimeric G-proteins, PI3kinase, and eNOS (55, 128, 209). The work described in the following
chapters will explore the hypothesis that caveolar "signalosomes" provide a
means of scaffolding and delivery of the message of ouabain- or bradykinininduced cardioprotection to mitochondria.

1.5 Research focus and synopsis
In this study I present a hypothesis for signal transduction in a cardiac
model. Specifically, it is proposed that hearts treated with the cardioprotective
agents ouabain or bradykinin are protected from the damage of a heart attack
because of the formation of a signalosome that serves to scaffold the signaling
enzymes into a platform that modulates the opening mitoKATP. Figure 1.3 is a
model based on the hypotheses discussed in the following pages.
This work begins with a description and analysis of the physiological
properties of the mitoKATP channel in heart. A description and comparison of
the cardioprotective profiles of the two study compounds, ouabain and
bradykinin, follows. The remaining chapters explore the signalosome
hypothesis in detail.
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Figure 1.3 Signalosome hypothesis. Upon binding to their receptors,
bradykinin and ouabain elicit the assembly of signalosomes that
phosphorylate thier receptors, R1 and R2, on the mitochondrial outer
membrane (MOM). Each signalosome contains its respective receptor and a
full complement of enzymes for their respective signaling pathway. The
terminal kinase of the bradykinin signalosome is PKG, which phosphorylates
R1 at a Ser/Thr residue. The terminal kinases of the ouabain signalosome
are Src and PKCs, which act in parallel to phosphorylate R2 at a Tyr and
Ser/Thr residue, respectively. Following phosphorylation of the outer
membrane, the mitochondrial PKCs (PKCsl) is activated by an unknown
mechanism. Activation of PKCsl phosphorylates mitoKATP and causes it to
open, with consequent increase in production of protective H 2 0 2 (4). The
H 2 0 2 then activates PKCs2, which leads to reduction in necrosis through
inhibition of the mitochondrial permeability transition (MPT) (32).

Bradykinin
signalosome

Ouabain
signalosome
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2. The Direct Physiological Effects of MitoKATP Opening on Heart
Mitochondria1

2.1 Summary
As much of the work presented in the following chapters will address the
physiological roles of the mitochondrial ATP-sensitive K+ channel (mitoKATP),
this chapter will provide a description of the direct physiological effects of
channel opening in mitochondria. MitoKATP has been assigned multiple roles
in cell physiology and in cardioprotection. Each of these roles must arise from
basic consequences of mitoKATP opening that should be observable at the
level of the mitochondrion. MitoKATP opening has been proposed to have
three direct effects on mitochondrial physiology — an increase in steady-state
matrix volume, respiratory stimulation (uncoupling), and matrix alkalinization.
Here, we examine the evidence for these hypotheses through experiments on

1

This material has been published in this or similar form in the American Journal of
Physiology, Heart and Circulation Physiology and is used here with permission from the
American Physiological Society:
Costa AD, Quinlan CL, Andrukhiv A, West IC, Jaburek M, Garlid KD. The direct physiological
effects of mitoK(ATP) opening on heart mitochondria.. Am J Physiol Heart Circ Physiol. 2006
Jan;290(1):H406-15.
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isolated rat heart mitochondria. Using perturbation techniques, we show that
matrix volume is the consequence of a steady-state balance between K+ influx,
caused either by mitoKATP opening or valinomycin, and K+ efflux caused by the
mitochondrial K7H+ antiporter. We show that increasing K+ influx with
valinomycin uncouples respiration like a classical uncoupler with the important
difference that uncoupling via K+ cycling soon causes rupture of the outer
mitochondrial membrane and release of cytochrome c. By loading the
fluorescence probe PBFI into the matrix, we show directly that K+ influx is
increased by diazoxide and inhibited by ATP and 5HD. By loading the
fluorescence probe BCECF into the matrix, we show directly that increasing K+
influx with either valinomycin or diazoxide causes matrix alkalinization. Finally,
by comparing the effects of mitoKATP openers and blockers with those of
valinomycin, we show that four independent assays of mitoKATP activity yield
quantitatively identical results for mitoKATP-mediated K+ transport. These
results provide decisive support for the hypothesis that mitochondria contain
an ATP-sensitive K+ channel and establish the physiological consequences of
mitoKATP opening for mitochondria.
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2.2 Introduction
The mitochondrial ATP-sensitive K+ channel (mitoKATP) is a receptor for
KATP channel openers (72) and blockers (94). Their identification and
subsequent use in the perfused heart model (71) provided strong evidence for
the hypothesis that mitoKATP opening protects the perfused heart against
ischemia-reperfusion injury. Thus, the mitoKATP-selective openers, diazoxide
and BMS191095, were found to be cardioprotective (71, 81), and the
mitoKATP-selective blocker, 5-hydroxydecanoate (5HD), was found to block
protection by both ischemic preconditioning (8, 80) and KATP channel openers
(71). MitoKATP has been proposed to play multiple roles in cardioprotection
(69, 159), and the mechanisms underlying these roles must arise from one of
the direct effects of mitoKATP opening on mitochondrial physiology. We have
proposed three effects of increasing K+ influx in normoxic mitochondria —
matrix swelling, mild uncoupling, and matrix alkalinization (70). Important
aspects of cardioprotection have been attributed to each of these effects.
Matrix swelling is a simple osmotic consequence of net uptake of K+
and phosphate into the matrix. The K7H+ antiporter is designed to balance K+
uptake and thereby provide volume homeostasis (70). We have proposed that
the K7H+ antiporter can only be activated by increased volume itself, so it
follows that increasing K+ influx should cause volume to move to a higher
steady-state value with greater underlying K+ cycling, which, in turn, will lead to
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increased energy dissipation (uncoupling). The concept that uncoupling
through K+ cycling is necessarily associated with matrix swelling has not
previously been explored.
It has been known for some time that scavengers of reactive oxygen
species (ROS) block cardioprotection (9, 30, 165, 221), leading Downey and
coworkers to propose that mitoKATP opening is a trigger of cardioprotection
(165) via mitoKATP-dependent ROS signaling. Our finding that mitoKATP
opening leads to a moderate increase in mitochondrial production of reactive
oxygen species (ROS) in cardiomyocytes (64, 217) has been confirmed in
vascular smooth muscle cells (117) and perfused hearts (56, 155). Thus,
mitoKATP opening causes an increase in mitochondrial ROS, which serve as
second messengers to activate kinases within the cardioprotective signaling
pathway (43). We have hypothesized that the increased ROS production is
caused by matrix alkalinization secondary to increased K+ influx (70); however
matrix alkalinization secondary to mitoKATP opening has not yet been
demonstrated.
We have investigated the physiological consequences of increasing the
K+ conductance of the inner membrane in isolated rat heart mitochondria, with
the following results: [a] Steady-state perturbation experiments show that
changes in K+ conductance cause mitochondrial volume to move between true
steady states in which total K+ influx equals total K* efflux via the K7H+
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antiporter. [b] The increased K+ cycling caused by mitoKATP opening leads to
very limited uncoupling that is associated with matrix swelling. We have found
a very narrow margin of safety between K+ uptake due to mitoKATP opening
and K+ uptake that causes cytochrome c loss due to matrix swelling and outer
membrane rupture, [c] K+ influx caused by mitoKATP opening is demonstrated
directly, as measured with the matrix-loaded fluorescence probe, PBFI. [d]
MitoKATP opening leads to matrix alkalinization, as measured with the matrixloaded fluorescence probe, BCECF. [e] The effects of ATP, diazoxide, and
5HD on K+ flux in heart mitochondria are shown to be qualitatively and
quantitatively the same when measured by four independent techniques —
light scattering, respiration, K+ flux, and H+ flux. These results lay the
groundwork for studies of how the direct physiological consequences of
mitoKATP opening are translated into cardioprotection.
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2.3 Methods
Mitochondrial isolation
Two male Sprague-Dawley rats (220 - 240 g) were anesthetized with
C0 2 and immediately decapitated. The hearts were removed and washed in
ice-cold Buffer A (250 mM sucrose, 10 mM HEPES pH 7.2, and 5 mM KEGTA). The tissue was finely minced in the presence of 1 mg/ml protease
(type XXIV Sigma), and the suspension was diluted 3-fold with Buffer A
supplemented with 0.5% fatty acid-free BSA. We observed that mitoKATP
activity depends critically on the time between decapitation and completion of
homogenization. This period was kept as brief as possible and was
completed within 2 min. The suspension was homogenized with a motorized
teflon pestle and centrifuged for 3 min at 1500 g. The supernatant was
centrifuged for 5 min at 9000 g, and the resulting pellets were resuspended in
Buffer A lacking BSA and centrifuged for 3 min at 2300 g. This supernatant
was centrifuged for 5 min at 9000 g. For respiration measurements and at
least one of each light scattering experiment, mitochondria were further
purified in a self-generating 28% Percoll gradient. The compact, hemoglobinfree mitochondrial pellet was resuspended at 35 - 40 mg protein/ml and kept
on ice. Mitochondrial protein concentration was estimated using the Biuret
reaction (75). This procedure is in accordance with the Guiding Principles in
the Care and Use of Animals and was approved by the IACUC at Portland
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State University.

Measurements of mitochondrial matrix volume and oxygen
consumption
Changes in mitochondrial matrix volume, which accompany net salt
transport into mitochondria, were followed using a quantitative light scattering
technique. This technique is based on the observation that the inverse
absorbance of the mitochondrial suspension (1/A), when corrected for the
extrapolated value at infinite protein concentration (1/A^), is linearly related to
matrix volume within well-defined regions (16, 67). Light scattering changes of
0.1 mg/ml mitochondrial suspensions were followed at 520 nm and 25 °C and
are reported as p, which is inverse absorbance normalized for protein
concentration, Ps:
P = P s (1/A-1/A 0O )
Mitochondria were suspended in a buffered salt medium containing K+,
tetraethylammonium (TEA+), Na+, or Li+ salts of CI" (120 mM), HEPES (10
mM), EGTA (0.1 mM), succinate (10 mM) and phosphate (Pj) (5 mM), pH 7.2.
The osmolality of these media ranged between 275 to 280 mOsm. For assays
of nonelectrolyte transport, mitochondria were suspended in the same
medium, except that 264 mM erythritol or malonamide was substituted for the
CI" salt. All media also contained 0.5 mM MgCI2, 5 \xM rotenone (to inhibit
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reverse electron transfer from Complex II to Complex I) and 0.67 jaM
oligomycin (to inhibit ATP synthesis by the F ^ - A T P synthase and the
consequent drecrease in membrane potential).
In these experiments, diazoxide (in DMSO) was always added to the
suspension 2 s after mitochondria to ensure even distribution of this
hydrophobic compound. It should also be noted that diazoxide is ineffective
unless ATP is already present, because the opener cannot open an already
open channel. Similarly, 5HD is ineffective unless ATP and an opener
diazoxide are also present, because 5HD does not itself block the channel, but
rather prevents the opening effect of diazoxide (94). The same observations
hold for cromakalim and glibenclamide. Light scattering traces were initiated
by addition of the mitochondrial suspension; the first 5-7 seconds of each
trace, containing the transient from the mitochondrial addition, were omitted for
clarity.
Oxygen consumption was measured with a Clark type electrode (Yellow
Springs Instruments) in a temperature-controlled chamber, using the same
buffered KCI medium described above and in the presence of ATP (200 p,M).
Oxygen concentration dissolved in our media was taken to be 480 ng atom 0 /
ml at 25 °C.

Measurement of'iC influx into PBFI-loaded mitochondria.
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The final mitochondrial pellet was resuspended to 20 mg/ml in Buffer A
supplemented with 10 mM pyruvate and 10 mM malate. This suspension was
incubated with 20 JJ,M Potassium Binding Fluorescent Indicator acetoxymethyl
ester (PBFI-AM), under stirring for 10 minutes at 25 °C. PBFI-AM was
dissolved in DMSO and mixed in a 2:1 ratio (v/v) with the non-ionic surfactant
pluronic F-127 in prior to addition to the mitochondrial suspension. The
mitochondrial suspension was then diluted to 5 - 7 mg/ml with TEA+ medium
containing 175 mM sucrose, 50 mM TEA-CI, 10 mM HEPES, 5 mM pyruvate,
5 mM malate, 5 mM succinate, 5 mM Pj, 0.1 mM EGTA, and 0.5 mM MgCI2,
and incubated for 2 minutes under stirring at 25°C. This incubation was
designed to substitute matrix K+ with TEA+ in order to bring matrix [K+] into the
sensitivity range of PBFI — under our experimental conditions, PBFI exhibited
an apparent Kd for K+ of about 8 mM, determined as in ref. (95). The brief
period of TEA+-loading had no effect on respiration or respiratory control. The
2 ml suspension was then diluted with ice cold Buffer A to 35 ml and
centrifuged twice at 10,000 x g for 3 minutes. The resulting pellet was
resuspended in Buffer A at 30 mg/ml and kept on ice. For the assays, aliquots
of this suspension (0.25 mg/ml) were transferred to 2 ml of the same
potassium medium used for the light scattering assay, at 25°C. PBFI
fluorescence, which increases with increasing K+ concentration (95) was
measured with an SLM/Aminco 8000C fluorescence spectrophotometer using
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an excitation ratio technique (Aex = 340/380, Aem = 500) in which the signal at
340 nm correspond to the maximal sensitivity of the probe to K+ and the signal
at 380 nm corresponds to isosbestic point of the probe. Ratiometric
measurements reduce variations in the measured fluorescence intensity that
may arise from competing factors, indicator concentration, excitation path
length, excitation intensity and detection efficiency (23). A calibration was
carried out on each preparation. The fluorescence ratios, R, were found to be
hyperbolically dependent on potassium concentrations, and were converted to
potassium concentration using the equation [K+] = Kd *(R - R0) / (Rmax - R).
where K^ is the dissociation constant (~ 8 Mm) experimentally determined, as
previously described (95). R0 is the fluorescence signal after lysis, and Rmax is
the maximum signal obtained after probe saturation with KCI.

Measurement ofpH changes in BCECF-loaded mitochondria.
Matrix pH was measured in isolated rat heart mitochondria as
described by Jung et al (102). Briefly, isolated rat heart mitochondria were
incubated with 8 pM 2',7' -bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein,
acetoxymethyl ester (BCECF, AM) in Buffer A for 10 minutes at room
temperature with stirring and oxygen access. The suspension was then diluted
10-fold with Buffer A and centrifuged at 9000 x g for 5 min to remove excess
probe. Mitochondria were then resuspended in Buffer A and stored on ice.
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Assays were carried with 0.25 mg/ml mitochondrial protein at 30 °C. BCECF
fluorescence, which increases with increasing pH, was measured with an
SLM/Aminco 8000C fluorescence spectrophotometer (Aex = 509, Aem = 535).

Statistical analysis
Data are presented as mean ± standard deviation (SD) of the mean.
Data were analyzed using unpaired Student's f-test of the means using
Microcal Origin software (Northampton, MA, USA). A value of p < 0.05 was
considered statistically significant.

Chemicals
PBFI-AM and BCECF-AM were obtained from Molecular Probes, Inc
(Eugene, OR, USA). Pluronic F-127 was obtained from Calbiochem (San
Diego, CA, USA). All other chemicals used were from Sigma Chemical Co.
(St. Louis, MO, USA).
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2.4 Results
The effects of ATP, diazoxide, and 5HD on matrix swelling are
potassium-specific.
The diagram in Fig. 2.1 describes the underlying processes by which
respiring mitochondria take up K+, phosphate, and osmotically obligated water
when suspended in potassium medium . K+ influx is driven by the proton
pumps of the electron transport chain and occurs via the parallel pathways of
diffusion and mitoKATP. K+ efflux is driven by the pH gradient and mediated by
the K7H + antiporter, which is regulated in such a way that its activity increases
with matrix volume. Therefore, K+ influx proceeds with matrix swelling until it is
matched by increased K+ efflux and a new steady-state volume is achieved
(70).
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Figure 2.1. The K+ cycle in heart mitochondria. In mitochondria respiring
in vivo or in vitro, electrophoretic K+ or TEA+ influx is always balanced by
electrogenic H+ ejection by the electron transport chain ("ETS"). During
steady-state K+ cycling, K+ influx via diffusion ("leak") and mitoKATP ("KATP") is
also balanced by K+ efflux on the K7H+ antiporter ("K/H"). The phosphate
transporter ("Pi") is highly active, such that Pj is in near-equilibrium with the pH
gradient (ApH). Thus, there is no net Pj movement associated with steadystate K+ cycling, because there is no change in ApH. Increasing K+ influx,
either by opening mitoKATP or by adding valinomycin, results in an imbalance
between K+ influx and efflux, causing matrix pH to increase. This leads to net
uptake of phosphoric acid via the phosphate transporter. Net salt uptake is
associated with osmotically obligated water, resulting in matrix swelling.
Matrix alkalinization releases the K7H+ antiporter from allosteric inhibition by
protons (17), and its activity increases to match the new level of K+ influx. The
system then reaches a new steady state at a higher matrix volume.
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Matrix swelling is proportional to net salt influx and leads to increased
light scattering (16, 67). Fig. 2.2A contains typical light scattering traces from
heart mitochondria respiring in K+ medium. In the absence of ATP ("none"),
the matrix swelled to a higher steady-state volume. Addition of 200 \xM ATP
resulted in a lower swelling rate and consequently a lower steady-state volume
("ATP"). ATP inhibition was reversed by 30 ^M diazoxide ("ATP + DZX"), and
the diazoxide-opening was blocked by 300 |aM 5HD ("ATP + DZX + 5HD").
The results obtained with the combination diazoxide + 5HD (Fig. 2A) were
reproduced by the combinations diazoxide + glibenclamide (10 \xM),
cromakalim (50 fj,M) + 5HD or cromakalim + glibenclamide (5 independent
experiments for each combination, data not shown).
Fig. 2.2 B contains typical light scattering traces from heart
mitochondria respiring in potassium-free TEA+ medium. Electrophoretic influx
of TEA+ occurs solely by diffusion. Because there is no efflux pathway for this
cation, mitochondria take up TEA+, phosphate, and water until K+ efflux via the
K7H+ antiporter equals TEA+ influx, at which point a steady-state volume is
achieved (at 60 - 90 s, Fig. 2.2 B). This steady state is short-lived, because
mitochondria soon lose all their K+ via K7H+ exchange, a phenomenon first
described in 1979 (66). After matrix potassium is exhausted (at about 120s,
Fig. 2.2 B), uptake of TEA+can no longer be balanced by K+ extrusion, and
matrix swelling proceeds at a rate proportional to the uncompensated TEA+
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influx. Note that light scattering in TEA+ medium is unaffected by ATP,
diazoxide, or 5HD (Fig. 2.2 B) and is also unaffected by cromakalim or
glibenclamide (not shown). We have also found in experiments not shown that
light scattering in Li+ or Na+ media is similarly unaffected by these agents.
Fig. 2.2 C contains light scattering traces from mitochondria suspended
in the same K+ medium as was used in Fig. 2.2 A. These data show that
inhibition of K+ influx by ATP or tetraphenylphosphonium cation (TPP+) is
reversed by the presence of 0.9 pmol valinomycin per mg of protein, and that
the matrix swelling induced by this concentration of valinomycin is qualitatively
and quantitatively similar to that induced by diazoxide in Fig. 2.2 A. Moreover,
5HD and glibenclamide (not shown) did not inhibit swelling caused by
valinomycin, confirming the mitoKATP-specific effects of 5HD. Glibenclamide
was also not able to inhibit swelling caused by valinomycin (not shown).
To further investigate whether ATP has artifactual effects on the light
scattering signal, we examined the effects of ATP on nonelectrolyte transport
in respiring mitochondria, with typical results contained in Fig. 2.3. Heart
mitochondria rapidly take up erythritol and malonamide with osmotically
obligated water, and malonamide is transported about 5 times faster than
erythritol, as previously shown in liver mitochondria (67). Note that
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Figure 2.2. K+-selective effects of ATP, diazoxide, and 5HD on matrix
swelling. Light scattering traces ((3) of rat heart mitochondria respiring on
succinate. (A) Mitochodria were respiring in K+ medium. The traces labeled
"none" and "ATP + DZX" are nearly superimposable, as are the traces labeled
"ATP" and "ATP + DZX + 5HD". (S) Mitochodria were respiring in TEA+
medium. All four traces are superimposable. (C) Mitochodria were respiring
in K+ medium and ATP was present in all traces. The traces "Val", "Val +
TPP+" and "Val + 5HD" are nearly superimposable, and the traces "none",
"TPP+" and "DZX + 5HD" are superimposable. Mitochondria were suspended
at 0.1 mg/ml and assayed as described in "Methods". ATP (200 ^M), TPP+
(0.5 jiM) and 5HD (300 jaM) were present at the beginning of each
corresponding trace. Diazoxide (30 piM) and valinomycin (0.9 pmol per mg of
protein) were added 2 seconds after the addition of mitochondria. These
traces are representative of at least 8 independent experiments.
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Figure 2.3. ATP has no effect on nonelectrolyte transport in heart
mitochondria. Light scattering traces (P) of rat heart mitochondria respiring
on succinate in malonamide orerythritol medium in the presence or absence
of 200 (j.M ATP. Mitochondria were suspended at 0.1 mg/mi and assayed as
described in "Methods". In these experiments, mitochondria swell due to
uptake of permeant nonelectrolyte and osmotically obligated water. The paired
traces ("+/- ATP") for each nonelectrolyte are nearly superimposable. These
traces are representative of 4 independent experiments.
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the presence of 200 ^M ATP had no effect on the rate of swelling, confirming
that ATP does not introduce an artifact into the light scattering assay when
added before the mitochondria. We also observed no effect of diazoxide or 5HD on matrix swelling in erythritol and malonamide (data not shown).

Perturbation of steady-state volume by modifying K+ flux
It was stated above that matrix volume approaches a steady state that
reflects underlying K+ cycling and that the K7H+ antiporter is volumedependent. We tested these assertions through steady-state perturbation
experiments. First, the putative steady state was perturbed with quinine, which
inhibits the K7H+ antiporter (68, 153). (Quinine may have other effects on
mitochondria; however it behaves in the predicted manner as a K7H+
antiporter inhibitor under all experimental conditions tested). It can be seen in
Fig. 2.4 A that addition of quinine is followed by a rapid swelling due to
uncompensated K+ uptake, confirming that the observed constant volume is
the result of steady-state potassium cycling. Subtle changes in steady-state
volume can also be elicited by increasing K+ influx or efflux with low
concentrations of valinomycin or nigericin, respectively (46). Typical results
from such experiments (Fig. 2.4 B) show, as expected, that valinomycin
induces matrix expansion while nigericin induces matrix contraction. When
quinine was added at the steady state, the resulting net flux must correspond to
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net K+ influx, which in turn must equal that part of the K7H+ exchange removed
by quinine inhibition. The results in Figs. 2.4 A and B therefore demonstrate
that K7H+ antiporter activity increases as matrix volume is increased.

The consequences of uncoupling via increasing activity of the K+ cycle
The K+ cycle (Fig. 2.1) catalyzes net proton influx, as do the classical
protonophoretic uncouplers, but the two processes are not identical in all their
effects. Fig. 2.5 contains data from mitochondria in which respiration was
titrated with the potassium ionophore valinomycin (Fig. 2.5 A) or the
protonophoretic uncoupler CCCP (Fig. 2.5 B) in the presence and absence of
10 nM cytochrome c. A typical feature of uncoupling, seen in both panels, is
that respiration increases up to the Vmax of electron transport, after which
respiration is constant (at high concentrations, CCCP inhibits electron
transport, as seen in the slight decline in rates at 500 nM CCCP). Note that
valinomycin is expressed in units per mg of protein, whereas CCCP is
expressed in molar units. The practical reason for this is that the valinomycin
partition coefficient between membrane and aqueous medium is very high, so
that most of the ionophore is in the mitochondria. CCCP is much less
hydrophobic and most of this ionophore is in the aqueous medium.
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Figure 2.4. Steady-state perturbations of mitochondrial matrix volume
by valinomycin, nigericin, and quinine. Light scattering traces ((3) of rat
heart mitochondria respiring on succinate in K+ medium. (A) The two
superimposed upper traces were obtained with no additions and with
diazoxide + ATP. The two superimposed lower traces were obtained with
ATP and with diazoxide + ATP + 5HD. To inhibit the K7H+ antiporter, quinine
(500 JJ,M) was added where indicated ("quinine"). (B) After a steady-state
volume was achieved, 1 pmol per mg of protein of nigericin (Nig) or
valinomycin (Val) were added ("ionophores"). After the new steady state was
achieved, quinine was added ("quinine"). Two superimposable traces for each
experiment are presented. Mitochondria were suspended at 0.1 mg/ml and
assayed as described in "Methods". Other conditions and concentrations of
tested compounds were exactly as described for Fig. 2.2. These traces are
representative of at least 4 independent experiments.
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Time (sec)
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Figure 2.5. Uncoupling of respiration by K+ cycling causes rupture of
the outer mitochondrial membrane. Oxygen consumption rates (Vresp) of rat
heart mitochondria respiring on succinate in K+ medium. (A) Valinomycin
titrations in the presence (o) or absence (i%) of cytochrome c. The dashed line
represents the rate of diazoxide-induced oxygen consumption (in the
presence (it) or absence (*) of cytochrome c), being equal to the rate
induced by about 1 pmol of valinomycin per mg of protein. (S) CCCP titration
in the presence ( • ) or absence (•) of cytochrome c. Exogenous cytochrome
c had little effect on oxygen consumption rates induced by CCCP; thus the
data points are nearly superimposable. Mitochondria were suspended at 0.25
mg/ml and assayed as described in "Methods". The data are shown as the
average ± S.D of 5 independent experiments.
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Several features of the data in Fig. 2.5 A are noteworthy, [a] The respiratory
rate induced by our standard concentration of diazoxide (dashed line in Fig.
5A) is about the same as that induced by 1 pmol valinomycin per mg of
protein, a result similar to that obtained with light scattering (Fig. 2.2) (115).
Similar rates of oxygen consumption were observed when 50 (iM cromakalim
was used instead of diazoxide (n=3, data not shown), [b] The respiratory
stimulation induced by diazoxide is a very small
fraction (less than 5%) of respiratory capacity, which is similar in magnitude to
diffusive leak of K+. [c] In the absence of added exogenous cytochrome c, no
further acceleration of respiration occurs at valinomycin concentrations greater
than 1.5 pmol/mg. Our interpretation is that the swelling consequent on
increased K+ cycling permeabilizes or ruptures the outer mitochondrial
membrane with the release of endogenous cytochrome c. The inner
membrane clearly remains intact, [d] The fact that exogenous cytochrome c
restores the acceleration of respiration confirms that the outer membrane (OM)
has become permeable to cytochrome c.
In contrast to the results with valinomycin, CCCP does not exhibit
dependence on added cytochrome c (Fig. 2.5 B). CCCP does not rupture the
OM at any concentration, because uncoupling by means of increased proton
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cycling has no direct effect on matrix volume, and the OM maintains its
integrity.

Net fC uptake causes matrix alkalinization.
Net K+ influx is balanced exactly by net electrogenic proton ejection by
the electron transport chain, leading to matrix alkalinization. This will be
partially compensated by electroneutral Pi uptake, which delivers protons to
the matrix. However, the cytosolic concentration of potassium is much greater
than those of P| and other substrate anions that undergo electroneutral
exchange across the inner mitochondrial membrane. Consequently, these
anion movements cannot fully compensate the alkalinizing effect of net K+
influx. We have hypothesized
that this normal imbalance must inevitably lead to matrix alkalinization as a
consequence of net K+ uptake via mitoKATP (70).
To test this hypothesis, we measured changes in both matrix [K+] and matrix
pH by loading the matrix with the K+-selective fluorescent probe, PBFI (95),
and the pH-selective fluorescent probe, BCECF (22). PBFI is insensitive to
changes in matrix K+ at normal levels of matrix [K+] (about 150 mM), because
the probe (Kd ~ 8 mM) is saturated at these levels, so we first depleted K+ by a
brief incubation in TEA+ salts with substrate (66), resulting in a matrix [K+] of 10
- 20 mM. This substitution had no effect on respiration rate or respiratory
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control (data not shown). One of the earliest reported features of the K7H+
antiporter is that it responds to changes in pH and volume, but not K+ (63, 66).
Thus, when part of matrix K+ is replaced by TEA+, the K7H+ antiporter
responds exactly as if the matrix contained all K+. This leads to the prediction
that the TEA+ will replace K+ and mitochondria will reach a new steady-state at
a lower K+ concentration. This is exactly what is observed, as shown in the K+
influx data in Fig. 2.6 A. The results of experiments measuring matrix pH are
reported in Fig. 2.6 B. The results obtained with diazoxide and 5HD (Fig. 2.6)
were duplicated by 50 ^M cromakalim and 10 pM glibenclamide, respectively
(n=3, data not shown). These results show directly that K+ channel openers
increase net K+ influx and that net uptake of K+ by respiring mitochondria
causes matrix alkalinization (70).
Four independent assays of mitoKATP activity in isolated mitochondria.
Our studies show that the effects of ATP, diazoxide, cromakalim,
glibenclamide, 5HD, and valinomycin on light scattering (Fig. 2.2 A and 2.2C)
are qualitatively identical to their effects on K+ influx (Fig. 2.6 A) and H+ efflux
(Fig. 2.6 B). These results also demonstrate that the effect of valinomycin on
these parameters affords a means of quantitating mitoKATP-dependent K+ flux.
Fig. 2.7 summarizes the results of experiments comparing diazoxide
with valinomycin in the light scattering assay (Fig. 2.7 A) and the respiration
assay (Fig. 2.7 B). In both assays, mitoKATP activity corresponded, by
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Fig. 2.6. K+ influx and matrix aikalinization induced by mitoKATP activity.
{A) Representative traces of PBFI-detected matrix K+ concentration. (B)
Representative traces of BCECF-detected matrix pH changes. Mitochondria
were loaded with either PBFI or BCECF and assayed at 0.25 mg/mi in K+
medium as described in "Methods". Where indicated, ATP (200 pJvl) and 5HD
(300 |uM) were present at the beginning of each trace. Diazoxide (30 ^M) and
valinomycin (0.9 pmol per mg of protein) were added 2 seconds after the
addition of mitochondria. Traces are representative of at least 4 independent
experiments.
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Fig. 2.7. Quantitative comparison of the light scattering and respiration
assays of mitoKATP activity. (A) Relative rates of matrix volume changes (LS
rate) in rat heart mitochondria respiring on succinate in K+ medium.
Mitochondria were suspended at 0.1 mg/ml and assayed as described in
"Methods". The rates in the absence and presence of ATP were set as 100
and 0%, respectively. (8) Oxygen consumption rates (Vresp) in rat heart
mitochondria respiring on succinate in K+ medium. Mitochondria were
suspended at 0.25 mg/ml and assayed in K+ medium as described in
"Methods". For both experiments, ATP (200 |aM), diazoxide (30 nM),
valinomycin (0.5, 1 or 1.5 pmol per mg of protein) and 5HD (300 |iM) were
present as indicated. Error bars represent standard deviations from the
average of at least three independent experiments. *p<0.05 vs control,
**p<0.05 vs ATP, ***p<0.05 vs Dzx.
200

r

sP

150h

£

100

CO

C/)

50 h

1.0

1.5

D)

o

E
o

CD

D)

c
ATP

Dzx Dzx+5HD

+ valinomycin

+ ATP

48

interpolation, to 1.0 ± 0.2 pmol valinomycin per mg of protein (5 independent
experiments). Fig. 2.8 summarizes the results from the PBFI (Fig. 2.8 A) and
BCECF (Fig. 2.8 B) experiments, together with a comparison with the effects
of 1 pmol valinomycin per mg of protein. In both assays, mitoKATP activity
corresponded again to 1.0 ± 0.2 pmol valinomycin per mg of protein (3
independent experiments). Thus, the data contained in Figs. 2.7 and 2.8 show
that four independent assays yield quantitatively identical results, establishing
not only the capacity of the endogenous ATP-inhibitable and diazoxideopenable K+ channel, but also the validity of each of these assays in monitoring
that capacity. These experiments were also duplicated by substituting
cromakalim and glibenclamide for diazoxide and 5HD (as described for Fig.
2.2 A, data not shown).
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Fig. 2.8. Quantitative comparison of PBFI and BCECF assays of
mitoKATP activity. (A) Relative rates of PBFI-detected K+ influx of rat heart
mitochondria respiring on succinate in K+ medium. (B) Relative rates of
BCECF-detected matrix pH changes of rat heart mitochondria respiring on
succinate in K+ medium. Mitochondria were loaded with either PBFI or
BCECF and assayed at 0.25 mg/ml in K+ medium as described in "Methods".
The rates in the presence of ATP were set as 100%. For both set of
experiments, ATP (200 p.M), diazoxide (30 ^M), valinomycin (1 pmol per mg of
protein) and 5HD (300 JJJVI) were present as indicated. Error bars represent
deviations
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2.5 Discussion
MitoKATP has been assigned multiple roles in cell physiology in general,
and in cardioprotection in particular (69). These include providing efficient
energy transfer between mitochondria and cellular ATPases (47), preservation
of ADP from deamination during ischemia (47), prevention of Ca2+ overload
(47, 89, 133), inhibition of the mitochondrial permeability transition (MPT)
(112), prevention of apoptosis (1), and cell signaling (159, 165). Each of these
roles must arise from direct effects at the level of the mitochondrion, and the
motivation for these studies was to examine in detail the direct physiological
effects of mitoKATP opening on isolated heart mitochondria. Three such effects
have been proposed —to increase matrix volume, to cause mild uncoupling,
and to cause matrix alkalinization (70). Any other effect must be downstream
of one or another of these three.
MitoKATP maintains matrix volume during ischemia. During
ischemia, the matrix will contract due to the decreased membrane potential.
Matrix contraction will cause reciprocal expansion of the intermembrane space
(IMS), resulting in increased outer membrane permeability to ADP and ATP,
which promotes rapid hydrolysis of cellular ATP by mitochondria. MitoKATP
opening increases potassium conductance to compensate for the lower
electrical driving force, thereby maintaining matrix volume, IMS volume, and
low outer membrane permeability to ATP and ADP. It was shown that
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mitoKATP opening causes a large overall reduction in ATP hydrolysis during
simulated ischemia, an effect that preserves adenine nucleotides by delaying
their degradation, thereby preserving ADP for an appropriate response to
reperfusion (47, 112). We also showed that segregation of ATP and ADP by
this mechanism increases the localized ATP hydrolysis within the
mitochondrial compartment, thereby lowering the membrane potential.
Membrane depolarization, in turn, will reduce Ca2+ uptake and prevent Ca2+
overload, as suggested by Liu, et al. (133) and Korge, et al. (112). The only
point of disagreement on this issue is the mechanism of the membrane
depolarization. Liu, et al. (133) and Korge, et al. (112) attribute it to
uncoupling. Although a significant uncoupling during ischemia cannot be
excluded, we have shown that the mitoKATP-dependent depolarization
observed in simulated ischemia is associated with reduced ATP hydrolysis.
This depolarization cannot be due to uncoupling, which would increase ATP
hydrolysis (47).
MitoKATP increases matrix volume during normoxia. As described
in Fig. 2.1, mitoKATP opening adds a parallel inner membrane K+ conductance
leading to increased K+ influx. K+ is accompanied by P| and water, leading to
matrix swelling, as shown by the light scattering traces in Fig. 2.2 A and in ref.
(115). The increase in matrix volume is inhibited by ATP; ATP inhibition is
reversed by KATP channel openers such as diazoxide; and channel opening is
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prevented by KATP channel blockers, such as 5HD. Attribution of these
responses to mitoKATP activity is supported by the finding that they do not
occur in K+-free medium (Fig. 2.2 B). Nor do they occur in K+ medium when K+
influx is increased with valinomycin (Fig. 2.2 C). As shown in Fig. 2.2 C,
mitochondria treated with valinomycin exhibit the same response as
mitochondria treated with diazoxide, except that the effects of valinomycin do
not require ATP and are not inhibited by 5HD.
Based on the known behavior of the K7H+ antiporter, we have asserted
that the increase in matrix K+ due to mitoKATP opening simply shifts matrix
volume to a higher steady-state value (70). The K7H+ antiporter is not very
susceptible to regulation by changes in its substrate concentrations, because
[K+] and [H+] do not change very much, even with rather large amounts of net K+
uptake (63). Instead, the antiporter is regulated allosterically by matrix [Mg2+]
(63) and [H+] (17), which sense changes in matrix volume (70). This means
that the K7H+ antiporter will mitigate, but not prevent, volume changes due to
increased K+ uptake. Fig. 2.4 contains strong support for this hypothesis.
Matrix volume was perturbed by opening and closing mitoKATP (Fig. 2.4 A) or
by adding ionophores (Fig. 2.4 B). The effects of quinine, which inhibits the
K7H+ antiporter (153), confirm that the preceding volume was a true steady
state and also demonstrate that K7H+ antiporter activity increases with
increasing matrix volume.
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MitoKATP opening causes mild uncoupling.

The steady-state K+

cycle described in Fig. 2.1 is a futile cycle and dissipates energy. We have
found that, provided K+ influx and efflux are balanced with the aid of
ionophores, the result of the futile K+ cycle is exactly the same as that of a futile
protonophoretic cycle caused by adding an uncoupler such as CCCP (data not
shown). However, when K+ influx and efflux must rely on endogenous
pathways, the results are not identical, as shown in Fig. 2.5. As valinomycinmediated uncoupling increases, the volume must also increase, as described
in the preceding section. This will eventually cause the outer membrane to
rupture with loss of cytochrome c and inhibition of respiration (Fig. 2.5 A). This
is not observed during CCCP-mediated uncoupling (Fig. 2.5 B), which is not
associated with matrix swelling. Valinomycin-induced uncoupling causes loss
of outer membrane integrity at about 1.5 pmol valinomycin per mg of protein,
and mitoKATP opening causes uncoupling at an equivalent valinomycin dose of
about 1 pmol per mg of protein (dashed line in Fig. 2.5 A). Thus, mitochondria
have a very narrow margin of safety with respect to K+ cycling, and a low
mitoKATP activity is essential for preserving the integrity of the outer
membrane. Indeed, the K+ flux catalyzed by mitoKATP is so small that it is
estimated to cause a decrease in mitochondrial membrane potential of only 1 2 mV in normoxic hearts (115). For this reason, we believe that a decrease in
membrane potential is not one of the significant effects of mitoKATP opening in
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the normoxic heart. Other laboratories have also shown that mitoKATP opening
does not cause detectable uncoupling of respiration in vivo or in isolated
myocytes (83, 123, 164).
MitoKATP opening causes matrix alkalinization. The theoretical
basis for the hypothesis that net K+ uptake results in matrix alkalinization is
best understood in the context of Fig. 2.1. Since overall transport must be
electroneutral, electrophoretic K+ influx will be balanced exactly by the
electrogenic H+ efflux driven by electron transport. If this were all that
happened, the K+ for H+ exchange would increase matrix pH by an amount
determined by the buffering power of the matrix (70). For example, if 20 mM
K+ were added to the matrix by this process, matrix pH would increase by
about 1 pH unit. But in fact, this loss of matrix protons is partially compensated
by electroneutral uptake of phosphoric acid via the Pi transporter. The
compensation is limited, however, by the fact that Pi is in equilibrium with the
pH gradient and, because the cytosolic concentration of Pi is much lower than
that of K+, Pi uptake is limited by its equilibrium distribution. For these
reasons, the P, equivalents taken up will always be less than those of K+ during
net K+ uptake, and it is this imbalance that leads to matrix alkalinization. The
data in Figs. 2.6 A and 2.6 B show directly that the increase in matrix K+,
mediated either by mitoKATP or by valinomycin, is accompanied by matrix
alkalinization. This effect is germane to the role of mitoKATP in
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cardioprotection, because matrix alkalinization appears to be the cause of
mitoKATP-dependent increases in production of reactive oxygen species (A.
Andrukhiv and K. D. Garlid, unpublished observations).
MitoKATP - its existence and its assay. The theoretical, experimental,
and quantitative basis of the light scattering assay for ion transport in
mitochondria were developed 20 years ago (16, 67), and application of this
assay to the study of mitoKATP was described 12 years ago (18). Despite a
robust body of evidence in support of this application (13, 18, 72, 94, 115), its
validity was recently questioned by Halestrap and coworkers (44). They carried
out light scattering experiments with heart mitochondria in which they observed
ATP inhibition of matrix swelling in K+ medium but failed to observe any effects
of diazoxide or 5HD. The latter finding caused these authors to raise the
question of whether mitochondria possess a KATP channel. To explain the
effect of ATP, they attributed the apparent inhibition by ATP to a light scattering
artifact rather than to inhibition of K+ flux.
The results in this chapter address these concerns as follows: [a] ATP,
diazoxide, cromakalim, glibenclamide and 5HD affect matrix swelling only in
K+ medium and not in TEA+, Li+, Na+ or nonelectrolyte media (Figs. 2.2A,
2.2B, 2.3, and data not shown), [b] ATP, diazoxide, and 5HD have no effect in
K+ medium when K+ conductance is increased by valinomycin. [c] Direct
measurement of K+ influx (Fig. 2.6 A) and the accompanying matrix
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alkalinization (Fig. 2.6 B) confirm the effects of ATP, diazoxide, cromakalim,
glibenclamide, and 5HD on K+ influx in mitochondria, [d] When valinomycinmediated K+ influx was used for calibration, mitoKATP-mediated K+ influx was
found to be quantitatively identical to that induced either by diazoxide or
cromakalim in four independent assays — light scattering, respiration, K+
influx, and H+ efflux (Figs. 2.7 and 2.8). In our judgement, these findings
provide decisive support for the existence of mitoKATP and for the validity of the
light scattering technique for its assay. This is very important, because light
scattering is the only practical means of studying K+ transport in isolated
mitochondria, and such studies are essential for future progress toward
understanding the role of mitoKATP in cardioprotection.
It seems likely that all of the effects of mitoKATP opening arise from
increasing the K+ conductance of the inner mitochondrial membrane, although
unrecognized consequences of protein-protein interactions cannot be
excluded. We believe that the only known direct effect of mitoKATP opening
during ischemia is to maintain matrix and intermembrane space volumes (47).
We have now established three direct effects of mitoKATP opening that occur
during normoxia — matrix swelling, mild uncoupling, and matrix alkalinization.
The unknown mechanisms by which mitoKATP opening confers
cardioprotection must ultimately derive from one of these effects, and it is
hoped that these findings will help in the search for these mechanisms.
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3. Ouabain protects rat hearts against ischemia-reperfusion injury via
a pathway involving src kinase, mitoKATPs and ROS2

3.1 Summary
This chapter introduces the cardioprotective profile of ouabain and contrasts it
to that of bradykinin. As these drugs are discussed in this context throughout
this text, this overview is important. Here, we investigated whether exposure to
ouabain was cardioprotective, and began to map the signaling pathways
linking ouabain to the opening of mitoKATP.
In Langendorff-perfused rat hearts, 10-80 jaM ouabain given before the
onset of ischemia resulted in cardioprotection against ischemia-reperfusion
injury, as documented by an improved recovery of contractile function and a
reduction of infarct size. In skinned cardiac fibers, a ouabain-induced
protection of mitochondrial outer membrane integrity, adenine nucleotide
compartmentation and energy transfer efficiency was evidenced by a
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decreased release of cytochrome c and preserved K1/2 (ADP) and ANT-miCK
coupling, respectively. Ouabain-induced positive inotropy was dosedependent over the range studied, whereas ouabain-induced cardioprotection
was maximal at the lowest dose tested. When compared to bradykinin (BK)induced preconditioning, ouabain was equally efficient. However, the two
ligands clearly diverge in the intracellular steps leading to mitoKATP opening
from their respective receptors. Thus, BK-induced cardioprotection was
blocked by inhibitors of PKG or guanylyl cyclase (GC), whereas ouabaininduced protection was not blocked by either agent. Interestingly, however,
ouabain-induced inotropy appears to require PKG and GC. Thus, 5-HD (a
selective mitoKATP inhibitor), MPG (a reactive oxygen species scavenger),
ODQ (a GC inhibitor), PP2 (a src kinase inhibitor), and KT 5823 (a Protein
kinase G inhibitor) abolished preconditioning by bradykinin and blocked the
inotropic response to ouabain. However, only PP2, 5-HD, and MPG blocked
ouabain-induced cardioprotection.

3.2 Introduction
Preconditioning the heart prior to prolonged ischemia results in protection
against ischemia-reperfusion injury. Preconditioning begins with activation of
cell surface receptors, which leads in turn to initiation of intracellular signal
transduction pathways. These have been extensively studied and reviewed by
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Downey and coworkers (29, 49, 152) and by Gross and Gross (79). The
signaling cascades lead to mitochondria, where they cause opening of
mitoKATP and subsequent release of ROS from mitochondria (4). Further
downstream effects occur, including inhibition of the mitochondrial permeability
transition (MPT) and prevention of cellular necrosis (32).
Ouabain, a member of the oldest class of drugs used in the treatment of
heart failure, has generally not been viewed as a potential cardioprotective
agent. Indeed, Ishida, et al. (92) employed high concentrations of ouabain to
induce Ca2+ overload in heart and to show that the toxic effects of Ca2+
overload were blunted by the mitoKATP opener diazoxide. Nevertheless,
several lines of evidence raised the possibility that ouabain may be
cardioprotective in the therapeutic dose range. First, it has been known for
several years that ouabain interaction with the Na,K-ATPase activates a
cellular signaling cascade (reviewed in (236)) that resembles the signaling
cascade of cardioprotection (69). Second, we showed that low concentrations
of ouabain stimulated mitochondrial production of reactive oxygen species
(ROS) in rat cardiac myocytes and that this ROS production was blocked by 5hydroxydecanoate (5-HD) (217). Third, we reported that mitoKATP is required
for increased contractility by various positive inotropic agents including
ouabain, further suggesting that wired mechanisms link the activation of Na,KATPase signaling complex to mitoKATP opening (73). Because mitoKATP
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opening and increased mitochondrial ROS production are critical for
cardioprotection, we decided to investigate whether ouabain is capable of
preconditioning the isolated rat heart.
At first glance, the physiology of inotropy and the pathophysiology of
cardioprotection appear to have little in common, but a closer analysis of
mitochondrial bioenergetics revealed that mitoKATP opening should be
critically important in both mechanisms. During both inotropic stimulation and
ischemia, the mitochondrial membrane potential (AUJ) decreases. As a
consequence, K+ diffusion into the matrix decreases and the mitochondrial
matrix contracts, resulting in an expansion of the mitochondrial intermembrane
space (IMS). IMS expansion disrupts the coupling between the outer
membrane voltage-dependent anion channel (VDAC), the inner membrane
adenine nucleotide translocase (ANT), and the mitochondrial creatine kinase
(miCK) leading to an increased outer membrane permeability to ADP and
ATP and decreased efficiency of energy transfer (47, 48, 69). Thus, energy
transfer from mitochondria to cytosolic ATPases is impaired when it is most
needed, whether during inotropic stimulation or reperfusion following ischemia.
This effect is prevented by mitoKATP opening, which prevents IMS expansion
by adding a parallel K+ conductance to compensate for the decrease in K+
driving force (47, 48, 69).
The present study focuses on ouabain-induced cardioprotection and
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begins an investigation of the signaling pathway involved. We show that
preconditioning with ouabain protects against infarction, protects heart
function, and preserves adenine nucleotide compartmentation in mitochondria.
We compared ouabain cardioprotection with the well-characterized
cardioprotection by bradykinin and found, through the use of inhibitors, that
both pathways depend on src kinase, mitoKATP, and ROS. We also observed
important differences in the signaling pathways for ouabain cardioprotection.
First, ouabain protection was not affected by inhibitors of cGMP-dependent
protein kinase (PKG) orguanylyl cyclase, whereas bradykinin protection was
abolished by these agents. Second, cardioprotection was more sensitive to
ouabain than was the inotropic response; that is, protection was observed at
ouabain concentrations that induced little or no inotropic response. Third,
whereas inhibitors of PKG or guanylyl cyclase had no effect on ouabaininduced cardioprotection, they abolished the inotropic response to ouabain.
These divergences suggest that the intracellular signaling steps leading to
mitoKATP opening differ between ouabain and bradykinin and, moreover, that
ouabain-induced increases in contractility require an additional signaling
pathway in parallel with that which opens mitoKATP.
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3.3 Materials and Methods
Chemicals and reagents
1 H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one (ODQ), KT5823 (KT), and
4-Amino-5-(4-chlorophenyl)-7-(f-butyl)pyrazolo[3,4-d] pyrimidine (PP2) were
purchased from Calbiochem (San Diego, CA). Bradykinin (Bk), ouabain
(Ouab), 5-hydroxydecanoate (5-HD), N-2-mercaptopropionyl glycine (MPG),
and all other reagents were all purchased from Sigma-Aldrich Corp. (St. Louis,
MO). 8-(4-chlorophenylthio)-guanosine 3',5'-cyclic monophosphate (CPTcGMP) was purchased from BIOLOG, Inc. (Hayward, CA).
Langendorff Perfusion
Different perfusion protocols were conducted in Bordeaux and Portland,
respectively (Fig 3.1). They differ slightly based on established practices in
each laboratory and required adaptations for preparation and analysis of
skinned fibers. The experimental protocols used in these studies were
performed in compliance with the American Physiological Society Guiding
Principles in the Use and Care of Animals and were approved by Institutional
Animal Care and Use Committee at Portland State University.
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Assessment of ouabain-induced cardioprotection and effects on
mitochondrial function.
Male Sprague-Dawley rats weighing 250 to 375g were anesthetized
with 40 mg of sodium pentobarbital injected intraperitoneally. The thorax was
opened, hearts were rapidly excised, immediately cooled in iced Krebs buffer
and perfused by an aortic canula delivering warm (37 °C), buffer at a constant
pressure of 100 mmHg. Hearts were perfused with a modified KrebsHenseleit solution containing in mM: NaC1118, KCI 5.9, CaCI21.75, MgS0 4
1.2, EDTA 0.5, NaHC0 3 25, Glucose 16.7. The perfusate was gassed with
95%0 2 - 5%C0 2 which resulted in a p0 2 above 600 mmHg at the level of the
aortic canula and a buffer pH of 7.4. The pulmonary artery was transacted to
facilitate coronary venous drainage and a left ventricular polyethylene apical
drain was inserted through a left atrial incision to allow Thebesien venous
drainage. Left ventricular pressure was monitored from a water-filled latex
balloon placed through the left atrial appendage, and connected to a Statham
P23Db pressure transducer. The volume of the balloon was adjusted to obtain
a left ventricular diastolic pressure around 7 mmHg and kept constant
throughout the entire experiment. Hearts were not paced and mechanical
performance was evaluated as the product of heart rate and developed
pressure (RPP).
Mitochondrial and heart function were assessed in five groups (n = 6 in
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each group) as described in Fig. 3.1, Protocol A. The control group was
perfused under aerobic conditions during 90 minutes. The ischemiareperfusion group (IR) was allowed to stabilize under aerobic conditions during
40 min prior to a 30-min zero-flow global ischemia period followed by 20 min
of reperfusion. The global zero-flow ischemia model was chosen in this case
because is it more adapted to the assessment of left ventricular functional
alterations and preparation of skinned fibers. Ouabain- treated groups (Ouab)
were allowed to stabilize under aerobic condition during 20 min, before 20 min
perfusion with a buffer containing ouabain. This was followed by 30 min zeroflow ischemia and 20. min reperfusion without ouabain. Mitochondrial function
was assessed on permeabilized fibers of left ventricle obtained immediately at
the end of the 20 min of reperfusion. Protocols for their preparation and assay
have been extensively described and discussed in earlier studies (47, 73,
222). Following incubation with saponin to permeabilize the muscle, fibers
were washed in buffer to remove adenine nucleotides, phosphocreatine, and
saponin. The oxygen consumption of skinned fibers (0.5-0.75 mg dry weight)
was measured polarographically at 25°C using a Clark-type oxygen electrode
(Oroboros oxygraph, Paar, Graz Austria). Data were recorded at sampling
intervals of 1 s (Datlab Acquisition Software, Oroboros, Innsbruck, Austria).
To determine control of respiration by ADP and creatine, oxygen
consumption of skinned fibers was measured in medium containing (in mM):
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CaK2EGTA 2.77 ; K2EGTA 7.23 (pCa =7); MgCI21.38 ; DTT 0.5 ; MES 100 ;
imidazole 20 ; taurine 20 ; KH2P04 3; pyruvate 10 ; and malate 5 mM. pH was
adjusted to 7.1 with KOH 10 M at 25° C and 2 mg/ml of bovine serum albumin
was added. To determine the half saturation constant of respiration for ADP
(K1/2 ADP), the dependence of respiration on ADP concentration in the
presence and absence of 20 mM exogenous creatine was calculated by
nonlinear regression (Kaleidagraph software).
To examine permeability of the outer mitochondrial membrane to
cytochrome c following ischemia-reperfusion, respiration was measured in 2
ml of KCI buffer containing (in mM): KCI 125 ; HEPES 20 ; pyruvate 10 ;
malate 5 ; Mg acetate 3 ; KH2P04 5 ; EGTA 0.4 ; DTT 0.3. pH was adjusted to
7.1 with KOH 10 M at 25 °C and 2 mg/ml of bovine serum albumin was added.
Respiration was stimulated by the addition of ADP at a final concentration of 1
mM, which induced a maximal activation. Cytochrome c was then added at a
final concentration of 8 mM to test the intactness of the outer mitochondrial
membrane.
Infarct size (IS) was determined in five groups of 4 to 6 hearts as
described in Fig. 3.1, protocol B. The ischemia-reperfusion group (IR) was
allowed to stabilize under aerobic conditions during 40 min prior to a 40-min
regional zero-flow ischemia period followed by 120 min of reperfusion.
Ouabain-treated groups (Ouab) were allowed to stabilize under aerobic
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condition during 20 min, before 15 min perfusion with a buffer containing
ouabain. This was followed by 40 min zero-flow ischemia and 120 min
reperfusion without ouabain. Regional ischemia was achieved by occlusion of
the left anterior descending coronary artery. The model of regional zero-flow
ischemia was chosen here to mimic the coronary artery occlusion encountered
in the clinical setting at the acute phase of myocardial infarction. The coronary
artery was reoccluded at the end of reperfusion, and the area at risk (AAR)
was determined by negative
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Figure 3.1 Rat heart perfusion protocols.
Timing of interventions is shown in relation to the zero-flow ischemia.
Protocol A was used to characterize the protective effect of ouabain on
heart function (see figure 3.2), in relation with mitochondrial respiratory
function in skinned fibers prepared after 20 min reperfusion (see figures
3.4 and 3.5). Ouabain (Ouab) concentrations were 10 p,M, 20 p,M, or 80
uM. Protocol B was used to address the question of the role of mitoKATP in
ouabain effect and compare the mechanism of ouabain preconditioning to
bradykinin preconditioning. After ischemia, all hearts were reperfused with
standard Krebs-Henseleit solution for 120 min (see figure 3.3 and 3.6-8).
Ouabain concentrations were 1 nM,10 uM, 20 uM, 50 uM,80 uM, or 1 mM.
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staining after perfusion of phtalocyanin blue (SP chaux, matiere & couleurs,
Bordeaux, France). This allowed for the delineation of the normal, aerobically
perfused area, stained blue, versus the AAR, not stained. The heart was then
removed from the perfusion apparatus, rinsed of excess blue dye, trimmed of
right ventricle and atrial tissue, and cut into six cross-sectional pieces. Slices
of the left ventricle were incubated without agitation in 1 % (w/v)
Thiphenyltetrazolium chloride (TTC) solution for 12 min at 37°C and pH 7.4.
TTC stains the viable tissue in a brick-red color, which allows the
discrimination between viable (red) and nonviable (pale yellow) tissue. The
samples were then fixed in 3.5% (w/v) formalin solution for 24 hours at 4°C and
weighed. Both sides of each slice were photographed. The area of each
region, delineated with SigmaScan Pro software were averaged from the
photographs of each side for each slice and multiplied by the weight of the
slice. Infarct size was finally expressed both as percentage of total left
ventricular mass and as a percentage of AAR.
Comparison of ouabain- and bradykinin-induced cardioprotection
Perfusion conditions were identical with those in Bordeaux with slight
modification in the perfusion buffer containing in mM: NaCI 118.5, KCI 4.7,
MgS0 4 1.2, KH 2 P0 4 1.2, NaHC03 25, CaCI21.7, glucose 10, and pyruvate
1.2, gassed with 95% 0 2 -5% C0 2 . Ten groups of hearts were studied (n = 3-6
in each group) as described in figure 3.1B. Following stabilization and
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pretreatment, all groups were exposed to 25-min zero-flow global ischemia
followed by 120 min of reperfusion with standard Krebs solution. The
ischemia-reperfusion group (IR) was allowed to stabilize under aerobic
conditions for 40 min. Prior to ischemia, the ouabain- (Ouab) and bradykinin(BK) treated groups were allowed to stabilize under aerobic conditions for 25
min, followed by 15 min perfusion with a buffer containing 50 mM of ouabain or
100 nM bradykinin, respectively. Where used, ODQ (2 |aM), 5-HD (300 ^M),
KT5823 (1 nM), MPG (1 mM), or PP2 (1 jiM) were added to the perfusate 5
min before ouabain or bradykinin, and included in the perfusate during the
subsequent 15 min perfusion with ouabain or bradykinin. In the experiments
with the PKG activator, CMP-cGMP was added simultaneously with ODQ 5
min before the additon of ouabain.
The hearts in each group were reperfused for 120 min after which
infarct size was estimated by the method of Ytrehus, et al. (241). 15 ml of 1%
wt/vol TTC in phosphate-buffered saline pH 7.4 at 37 °C was infused into the
coronary circulation at a rate of 0.5 ml/gm/min. The eluted stain from the
cardiac veins was collected and recirculated. After approximately 15 min of
perfusion the epicardial surface was deep red. Hearts were then removed
from the cannula and fixed overnight in 10 % Formalin. Hearts were removed
from formalin, sectioned along the atrioventricular plane into ~1mm sections.
Sections were placed between two microscope slides and computerized area
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analysis was performed using Scion image and the infarct size of each heart
was expressed as a fraction of the total area at risk. Infarct size for each heart
was determined by averaging the infarct area of the 5-6 sections. The RPP
data shown if Fig. 3.8 were calculated using the average RPP measuredduring the 15-min drug treatment for each experimental condition (Figure 3.1
protocol B).
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3.4 Results
Effects of ouabain concentration on cardiac function
Hemodynamic data shown in Fig. 3.2 were obtained in experimental
conditions described in Fig. 3.1, protocol A. As shown in Fig. 3.2A, the control
group was hemodynamically stable, with less than 12% decline in RPP over
the 90-min perfusion period. The average control RPP was 33800 ± 1200 mm
Hg.min. Ischemia resulted in immediate cardiac arrest. Upon reperfusion, a
limited recovery of systolic function was observed with maximal RPP values at
the end of the reperfusion period corresponding to 17% of control values. As
shown in Fig. 3.2B, diastolic pressure remained constant in the control group.
In the IR group, ischemic contracture was observed after 15 min of ischemia
with a maximum of 24 ± 4 mm Hg (Figure 3.2B, p < 0.01 vs. control). Overall,
these data show the early occurrence of contracture during ischemia and a
poor early recovery of systolic function after reperfusion.
Perfusion of ouabain induced a concentration-dependent increase in
RPP (Fig. 3.2A), with the maximum increase (57%) being achieved with 80
uM ouabain. The inotropic effect was due exclusively to an increase in
developed pressure with no significant associated change in heart rate or left
ventricular diastolic pressure (not shown). All three doses of ouabain
prevented ischemic
72

Figure 3.2. Effects of ouabain on left ventricular function.
A: Rate pressure product (RPP), and B: left ventricular end diastolic
pressure (LVEDP) obtained from control, Ischemia-reperfusion (IR),
Ouab 10, Ouab 20, and Ouab 80 groups of Langendorff perfused rat
hearts. See "Materials and Methods" and "protocol A" of Fig. 3.1 for
details on perfusion protocols. Values are means of 6 separate
experiments. §= p < 0.05 vs IR.
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Figure 3.3. Effect of ouabain dose on infarct size.
Infarct size expressed as a percentage of the area at risk in Langendorffperfused rat hearts subjected to 40 minutes regional ischemia followed
by 120 minutes reperfusion as described in "Materials and Methods"
and "protocol B" of Fig. 3.1. * = p < 0.05ys. IR.

*

70

O
O

60
50
D£ 40

§*
30
o
CO

©$
o ^

*
i^l

20

Q

§

8
*
><,

10
0

X

IR

10 nM

*

o

1

8

4-

4-

10 MM

20 MM

Ouabain

80 pM

1tnM

Figure 3.4. Effect of ouabain on mitochondrial respiration in skinned
fibers.
Shown are respiration values measured in KCI medium in the absence of
ADP (black bars), in the presence of 2 mM ADP (gray bars), and in the
presence of 2 mM ADP + 10 uM cytC (dashed bars). See "Materials and
Methods" and "protocol A" of Fig. 3.1 for details on perfusion protocols. $
indicates p < 0.05 vs. Control; * indicates p < 0.05 vs. State 3 IR.
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Figure 3.5. Effect of ouabain on control of outer membrane permeability
toADP.
K1/2ADP for respiration was assessed as a measure of outer membrane
permeability to ADP in the presence (hatched bars) or absence (black bars) of
20 mM creatine. Respiration was evaluated in permeabilized fibers prepared
from the left ventricle of isolated rat hearts, as describe in "Materials and
Methods" and "protocol A" of fig 3.1. * indicates p <0.05 vs IR, and tindicates
p<0.05 vs in presence of creatine.
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contracture during index ischemia (Fig. 3.2B) and significantly improved
functional recovery upon reperfusion (Fig. 3.2A).
Effects of ouabain on infarct size
The area at risk (AAR) was identical in each group (Figure 3.1 protocol
B) and averaged 28 ± 2 % of left ventricular mass. As shown in Fig. 3.3, 40
min ischemia followed by 120 min reperfusion resulted in an infarction of 29.8
± 2.5 % of the AAR. Fifteen min perfusion of 10, 20 or 80 |uM ouabain
immediately before ischemia significantly decreased the infarct size to 12 ±
1.7%, 7.4 ± 2.1% and 11 ± 1.8% respectively (p < 0.05 vs IR). Perfusion of 10
nM ouabain did not afford any protection, whereas perfusion of 1 mM ouabain
exerted a toxic effect as evidenced by the significant increase in infarct size to
62 ± 6 . 4 % % of the AAR.
Effects of ouabain on mitochondrial function
Figure 3.4 contains results from assays of cytochrome c release (see
Materials and Methods). In the control group, maximal respiration was 26 ± 2
nmol 0 2 /min/ mg dw, and addition of cytochrome c did not induce any
stimulation. After 30 min ischemia followed by 20 min reperfusion, maximal
respiration was decreased by 16 % compared to control (p < 0.05). In these
fibers, the addition of exogenous cytochrome c accelerated respiration up to
the value measured in the control group. These data reflect alterations at the
level of the outer mitochondrial membrane leading to a loss of endogenous
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cytochrome c. It is to be noted that ischemia followed by reperfusion had no
effect on state 2
respiration rates. In the ouabain groups, maximal respiration was not
significantly decreased, and addition of cytochrome c did not produce any
stimulation. These data indicate that ouabain protected against cytochrome c
loss from mitochondria.
The data in Fig. 3.5 contain K1/2ADP values, determined in the presence
or absence of creatine (Cr), as described in "Materials and Methods". In fibers
from control hearts, the K1/2ADP value was 282 ± 10 uM. This high value reflects
restriction of permeability to ADP at the level of the outer mitochondrial
membrane. In the presence of Cr, this value decreased to 82 ± 7 uM. As
previously discussed, the Cr-induced decrease in K1/2ADP reflects functional
coupling between adenine nucleotide translocase (ANT) and mitochondrial
creatine kinase (195). In fibers from the IR group, K1/2ADP was dramatically
decreased to 135 ± 8 uM (p < 0.05 vs. control), and decreased to 64 ± 2 uM in
the presence of Cr. In contrast, K1/2ADP in fibers from the ouabain-treated
hearts remained high, with values of 210 ± 23 |o.M (80 (iM ouabain) and 204 ±
29 uM (20 (iM ouabain). These values are significantly higher than the value
measured in fibers from the IR group, which reflects the preservation of the low
permeability of the outer mitochondrial membrane for ADP (47). Fibers
obtained from Ouab 10 group showed similar effects (data not shown).
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Addition of Cr resulted in a decrease in K1/2ADP to 57 ± 10 uM and 53 ± 4 uM,
respectively, in fibers from the ouabain-treated hearts, reflecting the
preservation of functional coupling of ANT and miCK, as observed in control
group.
Ouabain versus bradykinin in cardioprotection
Cardioprotection by ouabain is a newly described phenomenon. We
decided to begin an investigation of the signaling pathways involved in
ouabain protection by comparing it with the well-characterized effects of
bradykinin. Bradykinin and ouabain treatment caused improved post-ischemic
functional recovery (Figs. 3.6a and 3.6b) as well as reduced infarct size (Fig.
3.7). As shown by Krieg, et al. (118, 120), cardioprotection by bradykinin
involves src kinase, eNOS, guanylyl cyclase, PKG, mitoKATP and ROS.
Participation of these elements is confirmed by the data in Figs. 3.6 and 3.7,
in which bradykinin protection against cardiac dysfunction (Fig. 3.6) and .
infarction (Fig. 3.7) is shown to be abolished by PP2, a src kinase inhibitor
(86), ODQ, a guanylyl cyclase inhibitor (74), KT5823, a PKG inhibitor (103), 5HD, a mitoKATP blocker (94), and MPG, a free radical scavenger.
Ouabain protection against post-ischemic cardiac dysfunction (Fig. 3.6)
and infarct size (Fig. 3.7) was also abolished by PP2, 5-HD and MPG,
confirming participation of src, mitoKATP and ROS in ouabain cardioprotection.
Interestingly, however, ouabain protection was not abolished by ODQ or
79

KT5823, suggesting that signaling following administration of ouabain and
bradykinin follows different pathways from the plasma membrane to
mitochondria.
Ouabain protection versus ouabain-induced inotropy
Although this study was designed primarily to address cardioprotection
by ouabain, we were also struck by the effects of drugs on the positive
inotropic response to ouabain, which were observed in the pre-ischemic
phase (see Fig. 3.6a). As shown in Fig. 3.8, 5-HD blocked the inotropic
response, as previously shown (73). Additionally, the inotropic response to
ouabain was blunted by MPG, PP2, KT5823, and ODQ. This data suggested
that the positive inotropic effect of ouabain was mediated by PKG. To test
this, we perfused with the cell-permeant cGMP CPT-cGMP in additon to ODQ
and ouabain. This reinstated the positive inotropic effect of ouabain that had
been inhibited by ODQ, confirming the requirement for PKG in ouabaininduced inotropy.
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Figure 3.6. Effects of ouabain versus bradykinin on left ventricular
function. (A) Functional cardiac recovery expressed as rate-pressure
product (RPP). (B) Post-ischemic LVDP plotted as the average pressure
(mm Hg) 30 minutes post-global ischemia, with error bars. See "Materials
and Methods" and "protocol B" of Fig. 3.1 for details on perfusion protocols.
100nM bradykinin (Bk) protection was blocked by 300 ^M 5-HD, 1 pM KT
5823 (KT), 1 mM MPG and 2 jaM ODQ. Neither ODQ nor KT blocked 50 uM
ouabain (Ouab) afforded cardioprotection, but 5-HD, MPG and PP2 blocked
functional recovery. N is at least 4 in all trials. * indicates p <0.05 vs. control.
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Figure 3.7. Differential effects of agents on ouabain versus
bradykinin cardioprotection.
Infarct size is presented as percent of risk zone in isolated adult rat hearts
subjected to 25 minutes global ischemia and 120 minutes reperfusion.
See "Materials and Methods" and "protocol B" of Fig. 3.1 for details on
perfusion protocols. Individual hearts (o) and group means (•) with
standard error bars are shown. Hearts treated with 100 nM bradykinin or
50 (4,M ouabain had significantly smaller infarct size than untreated
ischemia reperfusion (IR) hearts. In bradykinin treated hearts, this effect
was blocked by all inhibitors tested: 300 uM 5-HD, 1 uM KT 5823 (KT), 2
uM ODQ, 1 mM MPG, and 1 |LIM PP2. In ouabain treated hearts
protection was not blocked by ODQ or KT but was blocked by 5-HD,
MPG and PP2. N is equal to at least 4 in all trials. * indicates p < 0.05 vs.
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Figure 3.8. Differential effects of ODQ and KT5823 on ouabain-induced
inotropy.
The inotropic response of the hearts is expressed as average of rate-pressure
product (RPP) during the 15-minute drug treatment. The data have been
normalized to the initial RPP at t = 0. Bradykinin does not have a positive
inotropic effect; the positive inotropic response induced by 50 JIM ouabain
treatment was abolished by 300 ^M 5-HD, 2 uM ODQ, 1 mM MPG, 1 ^M
KT5823 and 1 fo.M PP2. The ODQ-inhibited positive inotropy was restored by
addition of the PKG activator CPT-cGMP (10 juM). * indicates p < 0.05 as
compared to ouabain, t indicates p<0.05 as compared to ODQ inhibited
ouabain.
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3.5 Discussion
Digitalis-like compounds have long been used in the treatment of heart
failure for their inotropic effects. We recently demonstrated that mitoKATP
opening is necessary for the positive inotropic response, including that caused
by ouabain (73). The implication of this result is that ouabain, like ischemic
preconditioning (IPC), causes mitoKATP opening by triggering an intracellular
signaling pathway. Because mitoKATP opening is cardioprotective, we
decided to investigate whether ouabain itself is cardioprotective and to begin
an investigation of its signaling pathway. The data in Figs. 3.2-5 show that
perfusion of ouabain, in the micromolar range, before ischemia-reperfusion
protects against infarction, protects heart function, and preserves adenine
nucleotide compartmentation in mitochondria. In this regard, treatment with
ouabain reproduces the effects of diazoxide and of ischemic preconditioning
previously described (47, 121). Ouabain in the nanomolar range did not
induce reduction in infarct size. This is in line with experiments performed on
myocytes showing that ouabain in the nanomolar range does not block, but
activates cardiac Na/K pumps (60). On the other hand, ouabain in the
millimolar range induced a toxic effect as evidenced by the significant increase
in infarct size shown in Figure 3.3. This might be explained by the damaging
effect of increased mitochondrial Ca2+ overload in this condition (92).
All or most cardioprotective signaling pathways rely on Src kinase (21,
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119, 226), mitoKATP (71, 156, 231), and ROS (9, 165, 221, 230), and it is dear
from the results in Figs. 3.6 and 3.7 that ouabain cardioprotection exhibits the
same requirements. Thus, the Src inhibitor PP2, the mitoKATP blocker 5-HD,
and the ROS scavenger MPG each blocks protection against contractile failure
and infarction after ischemia-reperfusion injury. In these respects, the effects
of ouabain were the same as the effects of bradykinin, compared in Figs. 3.6
and 3.7.
It is most interesting, however, that the signaling pathways for the two
ligands differ in important respects. Thus, bradykinin protection depends on
PKG and guanylyl cyclase (160), whereas ouabain protection does not. This is
manifested in the differential response to KT5823 and ODQ, inhibitors of PKG
and guanylyl cyclase, respectively, and the effect is seen in both functional
recovery and protection against infarction (Figs. 3.6 and 3.7). Addition of PKG
+ cGMP to isolated mitochondria is sufficient to open mitoKATP (31); however
these ligands appear not to be involved in the ouabain cardioprotective
pathway, so there must be more than one mechanism to signal mitoKATP
opening at the level of the mitochondrion. We infer from these studies that
mitoKATP opening is necessary and sufficient for cardioprotection by ouabain
and bradykinin.
Another original finding of this study is that KT5823 and ODQ inhibit the
inotropic effect of ouabain (Fig. 3.8), in contrast to their lack of effect on
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protection. This indicates that guanylyl cyclase and PKG are required for the
inotropic response to ouabain. We showed that ouabain causes mitoKATP
opening and mitochondrial ROS production (217) and, moreover, that
mitoKATP opening is necessary for the inotropic response (73). From these
results, we may conclude that mitoKATP opening is necessary, but not sufficient,
for the inotropic resonse.
Based on these findings and those from other studies, we infer that
ouabain activates two different signaling platforms, as described in Fig. 3.9.
One platform is the "mitoKATP-ROS platform" (4), which is activated by low
concentrations of ouabain, as detected by mitoKATP-dependent
cardioprotection. The other is a "Ca2+ regulating platform", such as has been
observed in renal cells (141, 242), which is activated by higher concentrations
of ouabain, as detected by the concentration-dependence of cardiac
contractility. The data presented here show that cardioprotection requires only
the mitoKATP-ROS signaling platform, whereas the inotropic response requires
both platforms. It has been known for several years that the signaling pathway
induced by ouabain through cardiac Na,K-ATPase relies on two intracellular
mediators: Ca2+ and ROS. Removal of Ca2+ from the medium inhibits the
ouabain-induced increase in intracellular Ca2+ in myocytes but does not affect
ouabain-induced ROS production (130), which is mediated by mitoKATP (217).
Thus, the two pathways exhibit a certain degree of independence. However,
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disruption of an upstream component of the cascade, such as the Na/KATPase /c-Src binary receptor (through inhibition of c-Src for example),
prevents ouabain-induced increases in both Ca2+ and ROS, and, as shown
here, prevents ouabain-induced inotropy and cardioprotection.
It appears that the common element connecting the two pathways is
ROS, since mitoKATP-dependent ROS production is required for both
cardioprotection and inotropy (73). Although earlier work by Xie and
coworkers found no effect of N-acetyl-cysteine on contractility (216), a recent
study from the same group found that ouabain-induced prolongation of the
Ca2+ transient and increased contractility were blocked by N-acetyl-cysteine,
and these effects were mimicked by incubation with 10 |aM H202 (105). ROS
are known to inhibit or activate most of the Ca2+ channels and transporters of
the heart (reviewed by Zima and Blatter (245)); however levels of H202
achieved by mitoKATP are unlikely to reach 10 JIM. Moreover, a direct role of
ROS in inotropy cannot account for the participation of guanylyl cyclase and
PKG in the inotropic pathway, which implies a role for phosphorylation, either
of a Ca2+ transporter or of the contractile mechanism (154). PKCs are
activated by H 2 0 2 (32) and are an essential component of the Ca2+-regulating
platform (144), and it is possible that mitoKATP-dependent H202 serves the role
of activating a PKC in the system. Noland, et al. (154) showed that a PKC
phosphorylates troponin I to sensitize the contractile system to Ca2+, and Ogbi,
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et al. (157) showed that PMA -activated PKCe increased contractile amplitude
and increased the quiescent period between contractions in neonatal
cardiomyocytes. In summary, our results show that the mitoKATP-ROS platform
is activated at low concentrations of ouabain that do not increase contractility.
Although the precise role of increased ROS in this system remains to be
established, it may be required to activate a step within the Ca2+-regulating
platform, which then moves to increase cytosolic Ca2+ or Ca2+-sensitivity and
thereby initiate the inotropic response.
It is unclear at present how these mechanisms fit into the more
established view of ouabain's mechanism of action, in which inhibition of Na,KATPase leads to elevation of [Na+]i, which causes reduced Ca2+ extrusion
and, possibly, increased Ca2+ influx via the Na7Ca2+ exchanger (NCX) (20).
Thus, Philipson and coworkers (188) found that NCX activity is essential for the
action of cardiac glycosides, and Bers and coworkers (2) found that a Na+
gradient and a functional NCX is essential for glycoside-induced inotropy in
cardiac myocytes.
Our finding here that ouabain-induced inotropy is blocked by ROS
scavengers and inhibitors of Src, guanylyl cyclase, and PKG points to an
essential role of cell signaling in the inotropic response to ouabain. These two
sets of requirements are not, of course, mutually exclusive; however it remains
for future work to determine how they are interconnected.
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Figure 3.9. Proposed model of bradykinin and ouabain signaling in
the heart.
The figure shows the signaling platforms associated with the bradykinin
receptor (BK2) and the ouabain receptor (Na,K-ATPase). We propose that
bradykinin and ouabain induce formation of two different mitoKATP signaling
platforms that cause mitoKATP opening, an increase in mitochondrial ROS
production, and cardioprotection. The bradykinin mitoKATP platform includes
Src, PI3-k Akt, eNOS, PKC, GC and PKG. The ouabain mitoKATP platform
also relies on Src activation for its formation, but little is known about the
downstream components. In addition, and at higher doses, ouabain induces
a Ca2+ platform that mediates the positive inotropic response. Interestingly,
the ouabain-dependent Ca2+ platform requires ROS for activation and
appears to contain the same components as the bradykinin-dependent
mitoKATP platform.

MitoKATP platforms
lower
[ouabain]

Ca2+ platform
higher
[ouabain]
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In summary, we have shown that ouabain is cardioprotective in the
perfused rat heart model. The cardioprotective signaling pathway triggered by
ouabain leads to mitoKATP opening and mitochondrial ROS production, and
this pathway differs from that triggered by bradykinin in that guanylyl cyclase
and PKG are not involved in ouabain cardioprotection. The mitoKATP-ROS
pathway is also necessary, but not sufficient, for the inotropic response, and
we hypothesize that a second signaling pathway involving the Ca2+ regulating
platform is also necessary for inotropy. These new features of ouabain
signaling via the Na,K-ATPase clearly require additional investigation. Further
investigation is also necessary to reveal whether the preconditioning effect of
ouabain could explain, at least in part, why it remains more beneficial for the
treatment of heart failure patients than the other drugs of the inotropic class
(125, 240).
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4. Conditioning the Heart Induces Formation of Signalosomes that
Interact with Mitochondria to Open MitoKATP3

4.1 Summary
Perfusion of the heart with bradykinin triggers cellular signaling events
that ultimately cause opening of mitochondrial ATP-sensitive K+-channels
(mitoKATP), increased H 2 0 2 production, inhibition of the mitochondrial
permeability transition (MPT), and cardioprotection. We hypothesize that
bradykinin interaction with its receptor induces the assembly of a caveolar
signaling platform (signalosome) that contains the enzymes of the signaling
pathway and that migrates to mitochondria to induce mitoKATP opening. We
developed a novel method for isolating and purifying signalosomes from
Langendorff-perfused rat hearts treated with bradykinin. Fractions containing
the signalosomes were found to open mitoKATP in mitochondria isolated from
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untreated hearts via activation of a mitochondrial protein kinase C epsilon.
MitoKATP opening required signalosome-dependent phosphorylation of an
outer membrane protein. Immunodetection analysis revealed the presence of
the bradykinin B2 receptor only in the fraction isolated from bradykinin-treated
hearts. Immunodetection and immunogold labeling of caveolin-3, as well as
sensitivity to cholesterol depletion and resistance to Triton X-100, attested to
the caveolar nature of the signalosomes. Ischemic preconditioning, ischemic
postconditioning, and perfusion with ouabain, also led to active signalosome
fractions that opened mitoKATP in mitochondria from untreated hearts. These
results provide initial support for a novel mechanism for signal transmission
from plasma membrane receptor to mitoKATP.
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4.2 Introduction
Bradykinin protects the heart against ischemia-reperfusion injury by a
signaling process whose sequence has been well described by Downey and
coworkers (160). Interaction of bradykinin with its receptor causes activation
of phosphatidylinositol 3-kinase (PI3K), which phosphorylates membrane
phospholipids to yield phosphatidylinositol trisphosphate, which then activates
phospholipid dependent kinases (PDK), which in turn causes phosphorylation
and activation of Akt. Akt phosphorylates endothelial nitric oxide synthase
(eNOS), causing it to generate NO. NO activates soluble guanylyl cyclase
(GC), causing it to synthesize cGMP which then activates protein kinase G
(PKG). PKG acts on the mitochondrial outer membrane (MOM), causing
opening of inner membrane mitoKATP channels (31).
These temporal events take place within complex spatial domains. In
particular, the signal must be transmitted from the plasma membrane to
mitochondria through the cytosol. How does this occur? Cytosolic proteins
are extensively hydrated, and the organization of this water causes a phase
separation from bulk cell water. Minimization of the phase boundary, in turn,
causes proteins to coalesce within their common hydration phase (65). If the
proteins of the cardioprotective signaling pathway were randomly distributed in
the cytosol, they too would coalesce within the hydration phase. The concerted
sequential reactions of cardioprotection would be unlikely to take place by
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random diffusional collisions in this milieu. Accordingly, we suggest that the
signaling cascade is compartmentalized in a manner to promote metabolic
channeling and that the entire reaction sequence moves through the cytosol as
a unit. Thus, our working hypothesis is that cytosolic transmission of the signal
to mitochondria takes place via vesicular, multimolecular signaling complexes
called signalosomes (15, 55, 202). This hypothesis agrees with and extends
the proposal by Ping and coworkers (182, 225) that intracellular signaling
involves assembly and regulation of multiprotein complexes.
We show first that bradykinin treatment of perfused rat hearts caused a
persistent open state of mitoKATP that was reversed by exposing the inner
membrane to the phosphatase PP2A. If this open state was caused by in situ
interaction of signalosomes with mitochondria, as hypothesized, the
signalosomes should be recoverable for study. Indeed, we were able to
recover them from the mitochondrial suspension obtained from the treated
hearts. Fractions containing the putative signalosomes from bradykininperfused hearts were added to mitochondria from untreated hearts and found
to be functionally active. That is, they opened mitoKATP to the same extent as
diazoxide and also caused inhibition of the mitochondrial permeability
transition (MPT). These effects were blocked by the specific PKG inhibitor
KT5823, confirming that PKG is the terminal kinase of the bradykinin
signalosome. The purified signalosomes were dissolved by the cholesterol-
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binding agent methyl-p-cyclodextrin, and they were resistant to Triton X-100,
indicating their caveolar nature. This was confirmed by immunodetection
analysis showing the presence of caveolin-3, a marker for muscle caveolae
(214). The bradykinin B2 receptor was also found in the signalosomes
isolated from bradykinin-perfused hearts. The vesicular nature of the
signalosomes was verified by electron microscopy, which revealed entities
between 110 and 160 nm in diameter. Immunogold labeling showed a clear
enrichment of the vesicles with caveolin-3. Signalosome formation appears to
be a general phenomenon. We also recovered active signalosomes from
hearts treated with ischemic preconditioning, ischemic postconditioning, and
ouabain.
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4.3 Materials and Methods
Isolated heart perfusions. Hearts from male Sprague-Dawley rats
(200-220g) were perfused for 50-55 min as previously described (173).
Control hearts were perfused for 50 min with Krebs Henseleit buffer containing
(in mM) 118 NaCI, 5.9 KCI, 1.75 CaCI2, 1.2 mM MgS04, 0.5 EDTA, 25
NaHC03, 16.7 glucose at pH 7.4. The perfusate was gassed with 95% 0 2 5% C0 2 . Treated hearts were perfused for 25 min with Krebs Henseleit buffer,
then with buffer containing 100 nM bradykinin or 50 yM ouabain (173) for 15
min, followed by 10 min washout. The ischemic preconditioning (IPC) protocol
was established by two cycles of 5 min global ischemia followed by 5 min
reperfusion. Mitochondria were isolated promptly following the second
reperfusion. Ischemic postconditioning was performed as described by
Tsang, et al. (220), with 6 cycles of 10 s ischemia plus 10 s reperfusion. Infarct
size was also measured after each of these treatments and found to be
reduced to an extent similar to that reported elsewhere (121, 172). The
experimental protocols complied with the Guiding Principles in the Use and
Care of Animals published by the National Institutes of Health (NIH Publication
No. 85-23, revised 1996).
Mitochondrial Isolation. Mitochondria from treated and untreated
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donor rat hearts were isolated immediately following 50 min of Langendorff
perfusion and used to isolate signalosomes. Mitochondria from untreated
assay rat hearts were isolated without previous perfusion, purified in a Percoll
gradient and used to assay for signalosome activity. A standard differential
centrifugation isolation protocol was used (31). Mitoplasts were prepared
from isolated mitochondria by digitonin treatment as described by Schnaitman
et al (201). Briefly, an ice-cold 2% digitonin solution was added stepwise to
mitochondria stirring on ice for 8 min. The digitonin was then washed out by
dilution with mitochondrial isolation buffer (250 mM Sucrose, 10 mM HEPES
(pH 7.2), 1 mM EGTA) and pelleted at 10,000 x g. Verification that the
mitochondrial outer membrane (MOM) was disrupted was performed by
respiratory assay in the presence and absence of cytochrome C. Interfibrillar
mitochondria were prepared using a protocol slightly modified from Palmer, et
al, (166). Briefly, the first low speed pellet from the standard isolation was
resuspended in 150 mM KCI and 50 mM HEPES medium and rehomogenized with a tight-fitting teflon pestle. Following this step, the standard
isolation protocol described in chapter 2 was followed (35). Mitochondrial
protein concentration was estimated using the Biuret reaction (75).
Signalosome Purification. To determine if caveolar bodies
associated with mitochondria following bradykinin treatment, donor
mitochondria were further purified in a self-generated 24% Percoll gradient,
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resulting in a purified mitochondrial fraction and a low-density fraction called
light-layer (LL). The LL was postulated to contain the signalosomes (see Fig.
4.1) but also contained plasma membrane fragments and broken
mitochondria. To purify the signalosomes, we used the non-detergent
caveolae isolation protocol of Smart et al (207). Briefly, the LL fraction was
adjusted to 2 ml, mixed with 50% Optiprep in buffer A (250 mM sucrose, 20
mM TRIS-CI (pH 7.8), 1 mM EDTA), and placed in the bottom of a 12 ml
centrifuge tube (the sonication step
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Figure 4.1. Schematic representation of the experimental protocol.
Each experiment required a donor preparation and an assay preparation.
The donor hearts were perfused with or without bradykinin on a
Langendorff apparatus, as described in "Methods". The assay hearts did
not undergo Langendorff perfusion. Mitochondrial fractions from both
hearts were purified on a 24% Percoll density gradient. The light layers
(LL) from donor hearts were assayed for their ability to open mitoKATP in
assay mitochondria. In separate experiments, the LL were further purified
on an Optiprep gradient. These purified LL were used for light scattering
assays, immunoblot analysis, and electron microscopy.

Donor hearts
25' Stabilization

(No perfusion)

Mitochondrial isolation
24% Percoll gradient
light layer (LL)

mitochondria

Purified LL (PLL)

Assay hearts
Mitochondrial isolation
24% Percoll gradient
light layer

mitochondria

Light-scattering assay
Immunoblot, electron microscopy
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of the published protocol was eliminated). A 20-10% Optiprep gradient was
layered on top, and the tubes were centrifuged at 52,000xgr for 90 min.
Following centrifugation, the top 5 ml were collected and mixed with 4 ml of the
50% Optiprep solution. This mixture was then overlayed with a 5% Optiprep
solution and centrifuged again at 52,000xg for 90 min. The signalosome
fraction was identified as an opaque band at the 5% interface. Validation of
the purity of this fraction was demonstrated by Western blots that showed very
little mitochondrial VDAC contamination and an enrichment of caveolins (fig
4.8).
MitoKATP assays. MitoKATP activity causes mitochondrial swelling, due
to respiration-driven uptake of K+ salts and water, and these volume changes
were followed by light scattering, as previously described (16, 31, 35).
Mitochondria from untreated assay hearts were added at 0.1 mg/ml to medium
containing K+ salts of CI- (120 mM), HEPES pH 7.2 (10 mM), succinate (10
mM), and phosphate (5 mM) supplemented with MgCI2 (0.5 mM), 5 JIM
rotenone , 0.67 j^M oligomycin. LL or purified LL were added as indicated in
figures. Data are summarized in bar graphs as "MitoKATP activity (%)", given
by
100 x [V(x) - V(ATP)]/[V(0) - V(ATP)]
where V(x) is the observed steady-state volume at 120 s under the given
experimental condition and V(ATP) and V(0) are observed values in the

100

presence and absence of ATP, respectively. Statistical significance of the
difference of the means was assessed using unpaired Student's t-test. A
value of p < 0.05 was considered significant. It should be noted that mitoKATPdependent K+ flux has been validated by 5 independent measurements - light
scattering, direct measurements of K+ flux, H+ flux, respiration, and H202.
production. Each of these was found to yield quantitatively identical measures
of K+ flux, using valinomycin-induced K+ flux as a calibrating control (4, 35).
The LL are expected to contain microsomes and peroxisomes (139),
which may be a source of H202. Because H202 opens mitoKATP in a PKCsdependent manner (93). We examined whether the enzyme catalase (10
units/ml) and the reactive oxygen scavenger, mercapto-propionyl-glycine
(MPG, 0.3 mM) inhibited LL-dependent mitoKATP opening. This treatment had
no effect on the ability of the LL to open mitoKATP (n = 5).
LL-dependent mitoKATP opening depends on the amount of LL added.
The concentration-dependence was determined and the amount used in the
assay was sufficient to give a near-Vmax response. Importantly, the yield of LL
from one donor preparation was just sufficient to treat the mitochondria from
one assay preparation. Diazoxide was added at 30 |j,M, sufficient to yield a
Vmax response (72).
MPT assays. Opening of the mitochondrial permeability transition
(MPT) was synchronized by sequential additions to the assay medium
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described above of CaCI2 (100 fiM free Ca2+), ruthenium red (0.5 \iM, to block
further Ca2+ uptake), and CCCP (250 nM, to syncronize MPT opening) (32).
Rates of volume change were obtained by taking the linear term of a second
order polynomial fit of the light scattering trace, calculated over the initial 2
minutes after MPT induction by CCCP. MPT inhibition was calculated by
taking the Ca2+-induced swelling rates in the presence and absence of 1 |o,M
cyclosporin A as 100 and 0 %, respectively.

Immunoblot analysis. Immunoblots were performed as described
previously (93). 5 p.g of protein was separated by SDS-PAGE using 10%
acrylamide precast gels (BioRad) and transferred to polyvinylidine difluoride
membranes (Millipore) by semi-dry transfer at 12 volts for 50 min. Membranes
were blocked with 5% nonfat dry milk in 20 mM Tris-buffered saline and 0.5%
Tween-20 (TBS-T) and incubated with primary antibody over night in TBS-T
containing 5% BSA. The membrane was then incubated for one hour with the
appropriate secondary antibody conjugated to horseradish peroxidase in
TBS-T. The membranes were exposed to autoradiograph films, which were
scanned. The primary antibody dilutions were as follows: BK2 1:5000 (Santa
Cruz Biotechnology), Caveolin-3 1:10,000 (Affinity Bioreagents), VDAC
1:5000 (Affinity Bioreagents), Protein kinase G 1:20,000 (Stressgen), and
eNOS 1:500 (BD Transductions Labs).
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ImageQuant version 5.0 (Molecular Dynamics) was used to quantify
Western blots. Quantification of gel band intensities was initiated by drawing
rectangles around appropriate gel bands from the Western blots. By using the
method of local averages for background correction, the software reports band
intensities for each rectangle. The standard error of the mean for gel band
intensities was determined from 4 to 6 replicate Western blots and represents
the cumulative error for the total Western analysis assay.
Electron microscopy. For immunogold labeling, aliquots were
washed in 20 mM KCI, mounted onto carbon-coated copper grids and fixed for
10 min in 3% paraformaldehyde. The grids were then incubated with Trisbuffered saline containing 0.2% bovine serum albumin (TBS-BSA) for 30 min
and subsequently incubated with the primary antibody (20 p,g/mL mouse
monoclonal caveolin-3; BD Transduction Labs) in TBS-BSA for 30 min. The
grids were washed three times for 5 min each in TBS-BSA and then incubated
with the secondary antibody (1:100 dilution of 10 nm gold-conjugated goat
anti-mouse IgG; Sigma) in TBS-BSA for 30 min. The grids were washed once
in TBS-BSA and five more times in distilled H 2 0. Control experiments were
performed by omission of the primary antibody (42, 187, 207, 229). Grids
were stained with 2% uranyl acetate, and examined with a JEOL TEM 100CX
microscope.
Chemicals. KT5823 and protein phosphatase 2A (PP2A) were

purchased from Calbiochem. The PKC isoform-specific peptides s V ^ and
UJeRACK were synthesized by EZ Biolabs (Westfield, IN), according to the
published amino acid sequences (27). Optiprep was purchased from AxisSchield PoC AS (Oslo, Norway). Bafilomycin A1, methyl-p-cyclodextrin and all
other chemicals were from Sigma.
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4.4 Results
Bradykinin perfusion opens mitoKATP by phosphorylation.
Bradykinin's cardioprotection is blocked by 5-hydroxydecanoate (5-HD) and
therefore presumed to require mitoKATP opening (160, 173); however this has
not previously been demonstrated. Bradykinin-treatment acts via PKG, which
interacts with mitochondria to open mitoKATP via a PKCs-mediated
phosphorylation (31). Thus, bradykinin perfusion should cause a persistent
open state of mitoKATP that is reversed by dephosphorylation. We isolated
mitochondria from bradykinin-perfused and sham-perfusion hearts and
prepared mitoplasts to permit access of the phosphatase PP2A to the inner
membrane, which cannot cross the mitochondrial outer membrane (MOM).
The results are presented in Fig. 4.2. In mitoplasts from untreated hearts
("sham perfusion"), mitoKATP was inhibited by ATP. As expected, ATP
inhibition was reversed by diazoxide, and PP2A had no effect (not shown). In
mitoplasts from bradykinin-treated hearts ("bradykinin perfusion"), mitoKATP
was resistant to inhibition by ATP unless PP2A was present (Fig. 4.2).
Bradykinin-dependent mitoKATP opening was maximal, as shown by the fact
that diazoxide had no further effect and by the finding that the bradykinindependent open state was equal to that observed in the presence of ATP +
PP2A + diazoxide. The data in Fig. 4.2 show for the first time that mitoKATP is
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Figure 4.2. Bradykinin-perfusion causes a persistent open state of
mitoKATP. Shown are changes in "% MitoKATP activity", calculated as described
in "Methods". Mitoplasts were prepared from mitochondria isolated from
perfused rat hearts, as described in "Methods". Mitoplasts from "shamperfused" (no treatment) and "bradykinin-perfused" hearts were compared for
the response of mitoKATP to ATP (0.2 mM), ATP + protein phosphatase PP2A
(11 ng/mL), ATP + diazoxide ("Dzx", 30 pM), and ATP + PP2A + Dzx. MitoKATP
from bradykinin-perfused hearts was open and unresponsive to ATP unless
PP2A was added. This indicates that the persistence of the open state was
due to phosphorylation. Data are averages ± SD of 3 experiments from 3
separate perfusions.
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opened ex vivo when the heart is perfused with a cardioprotective agent.
Purified LL from bradykinin-treated hearts open mitoKATP via PKG
and mitochondrial PKCe. To test whether the mitochondria-associated LL
contained signaling enzymes capable of opening mitoKATP, we added LL
aliquots to purified mitochondria from untreated assay hearts. The
representative traces in Fig. 4.3 show that both the LL and the purified LL from
bradykinin-treated hearts reversed the ATP inhibition and opened mitoKATP.
LL from untreated hearts ("sham LL") and residual LL ("RLL") from bradykinintreated hearts had no effect. (RLL contain the proteins that remained after
purified LL were isolated from LL).
Light scattering data from an extensive series of experiments are
summarized in Fig. 4.4. LL from control hearts ("sham LL)" and isolated
plasma membrane caveolae ("caveolae") had no effect on mitoKATP or on the
effect of diazoxide (n = 10). The LL from bradykinin-treated hearts ("bradykinin
LL") opened mitoKATP to the same extent as diazoxide (n = 10). Addition of
diazoxide plus the bradykinin-LL had no further effect, so the bradykinin LL
opened mitoKATP maximally. MitoKATP opening by the bradykinin-LL was
blocked by 5-HD, acting directly on the channel.
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Figure 4.3. LL and Purified LL from bradykinin-treated hearts open
mitoKATP in isolated mitochondria. Mitochondrial matrix volume is plotted
versus time. Aliquots of LL ("LL", 10-15 ug/ml), purified LL ("PLL", 0.5
|4.g/ml), and residual LL ("RLL", 10-15 |ag/ml) were added to medium one
second after the mitochondria. ATP (0.2 mM) was present in each run.
KT5823, a PKG inhibitor, was added at 0.5 jaM. Traces are representative
of at least 5 independent experiments. 6 separate traces are plotted in the
figure, and some of them are superimposed.
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Figure 4.4. Properties of LL-induced mitoKATP opening. Shown are
changes in "MitoKATP activity (%)". LL from sham-perfused hearts ("sham
LL") had no effect on mitoKATP activity (n = 3). Caveolae isolated from
untreated hearts (206) did not open mitoKATP at amounts up to 700 jig per
mg of mitochondrial protein. (Shown are data using 300 jag/mg of
caveolae, n = 3). The bradykinin LL induced mitoKATP-opening that was
inhibited by 5-HD (1.0 mM) and sV.,_2 (0.5 \M). Note that a higher
concentration of 5-HD is required to block mitoKATP after it has been
opened by phosphorylation (31). The bradykinin LL opened mitoKATP to the
same extent as diazoxide ("dzx"), and diazoxide had no additional effect in
the presence of the bradykinin LL. Bradykinin data are averages ± SD of at
least 4 independent experiments.
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It was also blocked by sV^, showing that LL-dependent mitoKATP opening
was mediated via PKCs. A complete set of experiments (N = 8) was also
carried out with the bradykinin purified LL (not shown), which exhibited results
identical to those of the bradykinin LL. For the practical reason that purified LL
are more time-consuming to prepare, we carried out the majority of functional
experiments using LL.
Expressed per mg of mitochondrial protein, LL from bradykininperfused and sham-perfused hearts were 130 ^g/rng and 100 ng/mg,
respectively. Purified LL from treated and sham were 8 p,g/mg and 3.7 jig/mg,
respectively. Thus, the LL purification removed 94% of the LL protein, and the
16-fold increase in specific activity of the purified LL shows a strong
purification of functionality. The 1:125 protein ratio (purified LL to
mitochondrial protein) permits a rough estimate to be made of the size of the
putative signalosomes. Assuming that the protein ratio is roughly equal to the
i

volume ratio, we calculate the diameter of the signalosomes to be about 140
nm, in excellent agreement with the size observed by electron microscopy,
described below.

LL recovered from hearts after ouabain perfusion, ischemic
preconditioning, and ischemic postconditioning open mitoKATP. We
carried out experiments with other models of cardioprotection in order to
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estimate the generality of this mechanism. We performed ischemic
preconditioning, ischemic postconditioning, or perfused the hearts with the
known protective ligand, ouabain (173), then isolated the LL and determined
their effects on mitochondria from untreated hearts. As can be seen in Fig. 4.5
(first bar of each group), each of these treatments led to signalosomes
capable of opening mitoKATP. LL-dependent mitoKATP opening by each
treatment was blocked by 5-HD and sN/^2, acting at the level of inner
membrane mitoKATP and PKCs, respectively (93) (not shown).
As shown in Fig. 4.5, the effects of bradykinin perfusion, ischemic
preconditioning, and ischemic postconditioning were blocked by KT5823,
indicating that these GPCR-coupled protective mechanisms act on
mitochondria via PKG contained in the signalosome. The mitoKATP opening
effects of ouabain LL were not blocked by KT5823, indicating that PKG is not
the terminal kinase of these signalosomes. This is in agreement with the
finding in perfused hearts that KT5823 blocked cardioprotection by bradykinin
but did not block cardioprotection by ouabain (173). In further experiments not
shown, we found that other models of cardioprotection, including acetylcholine
and elevated perfusate Ca2+ also led to LL that open mitoKATP (n = 1 to 3 for

111

Figure 4.5. LL-induced mitoKATP opening following IPC and ouabain
treatment. Shown are changes in "MitoKATP activity (%)" when bradykinin
LL, IPC LL, ouabain LL, or ischemic postconditioning LL were added to
assay mitochondria. Also shown are the effects of PP2A (11 ng/mL) and
KT5823 ("KT", 0.5 \xM) added to the assay. Note that PP2A cannot cross
the MOM of intact mitochondria, so the effect is on the MOM. Data are
averages ± SD of 3 to 4 independent experiments.
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each treatment).
Role of the mitochondrial outer membrane (MOM) in LL signaling.
As shown in Fig. 4.5, LL-induced mitoKATP opening was blocked in each case
by PP2A added to the assay medium. In these experiments, in contrast to
those of Fig. 4.2, the MOM was intact. Because PP2A cannot cross the MOM,
the results indicate that signalosome activity required phosphorylation of a
MOM protein. We used mitoplasts to study the effects of MOM removal on
mitoKATP opening by various treatments. The findings (not shown) may be
summarized as follows: MOM removal had no effect on diazoxide-induced
mitoKATP opening, but it abolished the abilities of PKG + cGMP and the
bradykinin, ouabain, and IPC LL to open mitoKATP. Thus the MOM is essential
for the action of the LL, and the effect of PP2A (Fig. 4.5) indicates that the LL
is phosphorylating a MOM protein, whose identity is not yet known.
LL from interfibrillar mitchondria of bradykinin-treated hearts
opens mitoKATP. Cardiomyocytes contain two populations of mitochondria,
subsarcolemmal (SSM) and interfibrillar (!FM), that exhibit subtle bioenergetic
differences (166). Standard isolation yields a primarily subsarcolemmal
population. We investigated whether active LL could also be isolated from
IFM, which largely supply ATP to contractile ATPases. We found that LL from
IFM opened mitoKATP to the same extent as diazoxide and otherwise behaved
identically with LL from SSM (data not shown, n = 5). Separation of SSM and
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IFM is imperfect; however, the fact that aliquots of LL from each fraction
opened mitoKATP maximally indicates that we were not studying a mixture of
active and inactive fractions.
Bradykinin LL inhibits the mitochondrial permeability transition
(MPT). The elevated calcium and ROS that occurs during ischemiareperfusion causes MPT opening, and this is inhibited by cardioprotective
agents (87). PKG-dependent MPT inhibition is a result of mitoKATP opening,
an increase in mitochondrial ROS production, and activation of an inner
membrane PKCs that inhibits MPT ((32) and see Fig. 4.10). Thus, ROS are
necessary for both initiation and prevention of MPT opening (32). As shown in
Fig. 4.6, the bradykinin LL inhibited MPT opening and did so to the same
extent as diazoxide. MPT inhibition by the bradykinin LL follows the same
pattern as was observed in Fig. 4.6 for mitoKATP opening - it is abolished by 5HD, KT5823, and PP2A.
Activity of the bradykinin LL Is sensitive to methyl-fi-cyclodextrin
and bafilomycin a1, but not to triton x-100. Hearts were treated with
bafilomycin A1, an inhibitor of receptor recycling (98), for 5 min prior to and
during treatment with bradykinin. LL and purified LL obtained from these
hearts failed to open mitoKATP (Fig. 4.7). Treatment of the LL with the
cholesterol binding agent, methyl-p-cyclodextrin, abolished LL-induced
mitoKATP-opening (Fig. 4.7) and dissolved the purified LL, as revealed by the
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Figure 4.6. LL-induced inhibition of the mitochondrial permeability
transition (MPT). LL inhibition of MPT in isolated heart mitochondria and the
effects of various antagonists are shown. Data are plotted as "MPT inhibition
(%)". Additions were: LL (10-15 jag/ml), diazoxide ("dzx", 30 ^M), 5-HD (0.3
mM), KT5823 ("KT", 0.5 ^M), and PP2A (11 ng/ml). Data are shown as
average ± SD of at least 4 independent experiments.
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absence of a pellet after centrifugation. Neither of these treatments affected
diazoxide-dependent mitoKATP opening, showing that the observed effects
were due to inactivity of the LL and not to mitochondrial damage caused by
adding the treated LL. To further characterize the nature of the purified LL, we
investigated its response to the nonionic detergent Triton X-100. Activity of
purified LL from bradykinin treated hearts was not affected by treatment with 1
% Triton X-100 (Fig. 4.7).
Presence of the bradykinin receptor and caveolin-3 in purified LL
from treated hearts. Mitochondria ("Mito") and purified LL ("PLL") from donor
hearts perfused with medium containing no bradykinin ("sham perfusion") or
bradykinin ("bradykinin") were obtained as described in Fig. 4.1 and
"Methods". As shown in Fig. 4.8A, the bradykinin receptor B2K was detected
uniquely in the bradykinin Purified LL, and caveolin-3 was strongly enriched.
The endothelial nitric oxide synthase (eNOS), a known component of
bradykinin signal transduction (160), was also found to be enriched in the
bradykinin fraction. PKG was found in all samples. Because the bradykinin
purified LL contains twice as much protein as the sham purified LL and the
same amount of protein was used for each sample, we estimate that the
purified LL from bradykinin-treated hearts contained about twice as much total
PKG as the purified LL from sham-treated hearts (Fig. 4.8B). VDAC was
used as a mitochondrial marker, and its immunoblots demonstrate minimal
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Figure 4.7. Bafilomycin A or methyl-p-cyclodextrin abolish LL-induced
mitoKATP opening, triton X-100 does not. Shown are changes in "MitoKATP
activity (%)". These experiments examine the effects of bafilomycin A (50 nM),
methyl-p-cyclodextrin (MCD) (5%) and Triton X-100 (1%) on mitoKATP opening
induced by bradykinin LL. Bafilomycin was added to the heart perfusate prior
to isolation of the LL. MCD, a cholesterol-binding agent, was incubated with
LL at 30°C for 5 min prior to assay. Triton X-100 was incubated with purified
LL for 10 min at 4° C. Prior to assay, the vesicles were pelleted in a
microcentrifuge (16,000 x g for 15 min), washed twice in dilute salt solution,
and resuspended in buffer without Triton X-100. Diazoxide ("dzx", 30 (iM) was
added at the same time as the LL aliquot (10-15 i^g/ml). Data are average ±
SD of at least 3 independent experiments.* indicates p<0.05 vs.
corresponding LL.
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mitochondrial contamination in both purified LL. Fig. 4.8B shows the result of
a densitometric analysis of the bands from six independent Western blots.
Immunogold labeling of caveolin-3 in the purified LL We
performed immunogold labeling studies using an antibody to caveolin-3. As
shown by the representative example in Fig. 4.9A, each vesicle was decorated
with several gold particles, indicating multiple copies of caveolin-3 in the
vesicles. Fig. 4.9B, obtained in the absence of primary antibody shows no
nonspecific binding of colloidal gold. Transmission electron micrography of
Triton X-100-purified LL was also performed to measure vesicle dimensions.
The mean diameter of the roughly spherical vesicles was 137 ± 25 nm (n =
48). The residual LL contained no vesicles. Purified LL from sham-perfused
hearts contained 15-20% as many vesicles as purified LL from bradykinintreated hearts, but these were ineffective in opening mitoKATP (Fig. 4.3).
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Figure 4.8. Immunodetection analysis of bradykinin signalosomes. (A)
Shown are representative immunoblots of 6 independent experiments. 5 (ig of
mitochondria protein ("MITO") from perfused untreated-hearts, or 5 jig purified
LL ("PLL") from untreated ("sham-perfusion") or bradykinin-treated
("bradykinin") hearts, obtained as described in "Methods", were loaded. For
each antigen, the signal shown was obtained on samples loaded on the same
gel and processed under the same conditions.
(B) Pixel density analysis performed on each band of N = 6 Western blots.
"BG" is the pixel density of a protein-free region of the blot.

Sham Perfusion

Bradykinin

Bradykinin B2
Receptor
-70 kDa
eNOS
-140 kDa

PKG
-80 kDa

VDAC
-31 kDa

Caveolin-3
-21 kDa

B
\ WKM Sham mito
;EZ3 Sham PLL
! Bradykinin PLL

2500

X
2000

c
0)
Q

15
a
O

1500-1
1000
500 ^

Ii
M

0

BkB2 eNOS PKG VDAC Cav3
119

Figure 4.9. Immunogold staining of bradykinin signalosomes.
Transmission electron microscopic analysis of purified LL from bradykininperfused hearts. Samples were applied to carbon-coated grids, fixed, and
processed for the presence of immunogold-labeling when treated either (A)
with the primary antibody caveolin-3 or (Mag = 100,000x) (B) without the
primary antibody, as a negative control (Mag = 67,000x).
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4.5 Discussion
The cardioprotective signal arising from bradykinin treatment is
transmitted from the bradykinin receptor to the mitochondrial outer membrane
(MOM), where it initiates the intramitochondrial signaling pathway described in
recent publications (4, 31-33, 93) and in Fig. 4.10. The objective of the
present study was to understand how the signal passes through the cytosol to
mitochondria. We propose that the pathway is mediated by signalosomes,
which are vesicular, multimolecular signaling complexes that are assembled in
caveolae and deliver signals to cytosolic targets, including mitochondria. We
first established that bradykinin treatment caused phosphorylation-dependent
mitoKATP opening in the donor mitochondria (Fig. 4.2). Using the protocols
described in Fig. 4.1, we then isolated functionally active signalosomes from
the same donor mitochondria. These were found to open mitoKATP in
mitochondria from untreated hearts (Fig. 4.3). This finding is consistent with,
but does not prove, the suggestion that these vesicles were responsible for the
mitoKATP opening that was observed in the experiments of Fig.4.2.
The remaining experiments of this study focus on the functional effects
of the isolated signalosomes, on their physical properties, and on the
generality of the signalosome mechanism. The signalosome-containing LL
and purified LL were able to open mitoKATP in mitochondria from untreated
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hearts to maximum capacity (Figs. 4.3 and 4.4). As expected from previous
results (31, 32), mitoKATP opening was blocked by 5-HD and e V ^ acting at
the level of the inner membrane (Figs. 4.4 and 4.10). Importantly, three
different control preparations had no effect on mitoKATP — a caveolar
preparation isolated from cardiac sarcolemma (Fig 4.4), purified LL from
untreated hearts (Figs. 4.3 and 4.4), and the residual LL (RLL) obtained after
removal of the purified LL from the LL preparation (Fig. 4.3).
MitoKATP opening by the bradykinin-LL was blocked by the PKG
inhibitor KT5823 (Fig. 4.5), confirming previous studies showing that PKG is
the terminal cytosolic kinase of the bradykinin signaling pathway (31, 32). LLdependent mitoKATP opening was also blocked by the Ser-Thr phosphatase
PP2A (Fig. 4.5), indicating that phosphorylation of a MOM protein is an
essential step in transmitting the signal to mitochondria. This was confirmed
by the further finding that removal of the MOM abolished all effects of LL on
mitoKATP activity (not shown). Thus, the effects of bradykinin-LL on mitoKATP
were identical to the previously reported effects of adding exogenous PKG
pluscGMP(31).
We have not yet identified the outer membrane target of PKG ("R1" in
Fig. 4.10), and we can only speculate on the nature of the link between
cytosolic PKG and mitochondrial PKCs. Several kinases have been
observed associated with mitochondria in the cardioprotected
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Figure 4.10. Signalosome hypothesis. It is proposed that interaction of
bradykinin with its receptor induces formation of a vesicular caveolar signaling
platform (signalosome) that phosphorylates a receptor (R1) on the
mitochondrial outer membrane (MOM). The identity of R1 is unknown. The
terminal kinase of the bradykinin signalosome is PKG, which phosphorylates
R1 at a Ser/Thr residue. Following phosphorylation of the MOM receptor, the
signal is transmitted across the intermembrane space to activate PKCsl on
the mitochondrial inner membrane. PKCsl, which is constitutively expressed
in mitochondria (32) and localized in close association with mitoKATP (123),
causes mitoKATP opening (31) and consequent increase in H 2 0 2 production (4).
The H 2 0 2 then activates a second PKCs, PKCs2, which leads to reduction in
necrosis through inhibition of the mitochondrial permeability transition (MPT)
(32).

Caveolar Bk2
• Caveolin

Bk2 receptor
\

Bradykinin \
signalosome /

123

phenotype. Increased phosphorylation of mitochondrial mitogen-activated
protein kinase (MAPK) has been observed, and PKCs has been shown to
phosphorylate VDAC, but the functional consequences of these observations
are not well understood (11, 12). Akt has been shown to phosphorylate
hexokinase-ll and modulate the MPT (142). Current experiments in our
laboratory indicate a role for a MOM MAPK in cardioprotective conditioning
mediated by the ouabain signalosome, but this MAPK is not involved in PKG
signaling. We have found that PKG-dependent signaling from R1 to PKCs
("PKCel" in Fig. 4.10) is not prevented by MPG, and therefore this step does
not involve ROS. The mechanism of PKCel activation is unknown; however,
PKCsl is activated by ysRACK (31), and we speculate that the connection
between R1 and PKCsl operates by a pseudo-RACK mechanism (receptor
for activated C kinase) (190).
Signal transmission by signalosome appears to be a general
phenomenon. Ischemic preconditioning, ischemic postconditioning, and
ouabain perfusion each lead to LL that open mitoKATP (Fig. 4.5). A limited
survery showed that perfusion with acetylcholine or elevated Ca2+ also lead to
LL that open mitoKATP.
The results of Fig. 4.6 show that the bradykinin LL causes inhibition of
MPT, which is widely thought to be responsible for cell death from ischemiareperfusion injury (38). We infer from this result that mitoKATP opening by the
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bradykinin signalosome mediates the MPT inhibition afforded by bradykinin
(168).
Both clathrin-mediated and caveolar-mediated endocytosis and
recycling depend on endosomal acidification by the vacuolar H(+)-ATPase
(98, 140, 211), which occurs when the vesicles pinch off from the plasma
membrane (140). Consistent with this, bafilomycin A1, a specific inhibitor of
the vacuolar H(+)-ATPase, prevented signalosome function (Fig. 4.7).
Interestingly, Western blots of the bradykinin purified LL were identical to those
obtained in the absence of bafilomycin (data not shown), in agreement with the
finding that bafilomycin blocks receptor return to the plasma membrane without
affecting receptor internalization (14, 98). This suggests that signalosomemediated delivery of the cardioprotective signal to mitochondria is a dynamic
process that requires both internalization and return to the plasma membrane.
Further investigation is warranted to test this hypothesis.
Resistance to Triton X-100 and sensitivity to methyl-p-cyclodextrin (Fig.
4.7), together with the Western blot data showing enrichment with caveolin-3
(Fig. 4.8), are consistent with a caveolar origin of the signaling platform (169,
205). The immunoblot analyses of Fig. 4.8 show that purified LL from
bradykinin-perfused hearts contain the bradykinin receptor BK2, caveolin-3,
PKG, and eNOS. Finally, electron microscopy of immunogold labeled purified
LL revealed that the vesicles contain multiple copies of caveolin-3 (Fig. 4.9).
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In general support of the signalosome hypothesis, there is considerable
evidence from a variety of cell types that activated G-protein-coupled receptors
first migrate to caveolae, where caveolins compartmentalize receptors and
signaling molecules (36, 53, 129, 134, 175, 184), assemble them into a
signaling platform (78, 225), and deliver the platform to the cytosol by
internalization (85, 134, 138, 183, 184, 219). The hypothesis is also
consistent with the findings of Tong, et al. (218), who showed that receptor
internalization and recycling are essential for cardioprotection by IPC.
Signalosome-mediated signaling has previously been postulated to occur in
heart in conditions other than cardioprotection (15, 55, 180, 202). The data
presented here appear to be the first demonstration of a specific functional
property of purified cardiac signalosomes.
These findings represent an initial step in our effort to apprehend the
organization of the complex signaling pathways of cardioprotection. The
signalosome hypothesis offers a new perspective for understanding and
studying cardioprotective signaling in the heart; however the concept remains
a working hypothesis that will require additional critical experiments to test its
predictions and validity.
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5. Ouabain cardioprotection is mediated by a signalosome mechanism
acting on mitochondrial p38-MAPK

5.1 Summary
This chapter serves to extend and strengthen the signalosome hypothesis for
cardioprotection. The digitalis-like cardiac glycoside ouabain activates an
intracellular signaling cascade that is cardioprotective. Ouabain
cardioprotection is mediated by the mitochondrial ATP-sensitive K+ channel
(mitoKATp), as well as kinases such as protein kinase C (PKC) and Src kinase.
This study explores the enzymatic components of the ouabain cardioprotective
pathway and proposes a hypothesis for their regulation. It is proposed that,
similar to bradykinin, a cardioprotective signalosome is formed upon treatment
with ouabain. The ouabain signalosome is a subfraction isolated from the
mitochondrial fraction of ouabain-treated hearts. It is characterized as a lowdensity membrane compartment that is enriched in caveolin-3, Src kinase, and
PKCs. Addition of the isolated signalosome to untreated mitochondria in an in
vitro assay of mitoKATP activity opens mitoKATP. This effect can be blocked by
inhibitors Src kinase, PKCs, and p38 mitogen-activated protein kinase (p38
MAPK). These data suggest that ouabain cardioprotection is mediated by a
p38 MAPK that is located in mitochondria and acting upstream of mitoKATP.
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5.2 Introduction
The Na,K-ATPase has two functions in cardiac physiology. It is an
energy transducer, using the energy from ATP hydrolysis to transport Na+ and
K+ across the cell membrane against their electrochemical gradients. When
activated by digitalis, the Na,K-ATPase is also a signal transducer, leading to
activation of PI3K/Akt pathways implicated in the control of both physiological
and pathological cardiac hypertrophy (132). The signaling function of the
digitalis-Na,K-ATPase complex also plays a role in digitalis-induced positive
inotropy. The accepted hypothesis for the mechanism of this effect is that
partial inhibition of the Na,K-ATPase leads to an increase in [Na+], that
exchanges with Ca2+ on the Na+-Ca2+ exchanger. The elevated [Ca2+]|, in turn,
acts on contractile proteins to increase contractile force (208). It was recently
shown that the inotropic response of the perfused rat heart to elevated Ca2+,
dobutamine, or ouabain was substantially inhibited by two different blockers of
the mitochondrial ATP-sensitive K+ channel (mitoKATP) (73). Similar effects of
mitoKATP inhibition on contractility were observed in rat cardiomyocytes (217)
and in human atrial fibers (73), implying that digitalis causes a signal to move
rapidly to mitochondria.
The signaling function of the digitalis-Na,K-ATPase complex also leads
to cardioprotection from ischemia-reperfusion injury (173, 181). Thus, ouabain
administered to the perfused rat heart before ischemia provided improved
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hemodynamic recovery and reduced infarct size after reperfusion. Similar
results have been obtained in the perfused rabbit heart (S. Pierre,
unpublished observations). Ouabain cardioprotection involves receptoractivated recruitment of protein kinases such as Src kinase and Protein kinase
C (PKC) into signaling complexes that mediate cardioprotection (173, 181,
215). Here again, the signal moves to mitochondria, because It has been
shown that ouabain cardioprotection requires mitoKATP activation and reactive
oxygen species (ROS) production.
In Chapter 4 of this study, I proposed that the signaling cascade in
response to bradykinin perfusion is assembled into a vesicular signalosome in
caveolae, after which it moves to mitochondria to open mitoKATP. We found
that hearts treated with bradykinin contained a mitochondria-associated
signalosome fraction that was recoverable for study (186). The signalosome
possessed a number of unique properties both biochemically and
physiologically, including its low-density caveolar nature as well as its ability to
open mitoKATP in vitro. In the exploration of this hypothesis we also found that
there was some generality to the proposed mechanism in that hearts that had
undergone ischemic preconditioning, postconditioning or ouabain treatment
also contained a signalosome fraction that was capable of opening mitoKATP
and inhibiting the mitochondrial permeability transition (MPT).
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In the present study, rat hearts perfused with ouabain yielded a
mitochondria-associated low-density signalosome fraction enriched in
caveolin-3, Src, PKCs and the a-subunit of the N+,K+-ATPase. We show that
this subfraction is capable of opening mitoKATP and inhibiting MPT in vitro.
We find that the signalosome-associated Src and PKCs behave as parallel
terminal kinases to phosphorylate a p38 mitogen-activated protein kinase
(MAPK) in the mitochondrial outer membrane (MOM) that resides upstream of
mitoKATP. In further exploration of the role of p38 MAPK, we find that ouabain
cardioprotection is blocked by the p38 MAPK inhibitor SB203580, and that
cardioprotection afforded by the MAPK activator anisomycin is blocked by the
mitoKATP blocker 5HD. These data support the hypothesis that ouabainmediated cardioprotection is acting through a signalosome mechanism to
activate a mitochondrial p38 MAPK.
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5.3 Methods
Isolated heart perfusions:
Male Wistar rats (200-220g) were anesthetized with carbon dioxide and
immediately decapitated. Hearts were rapidly excised, submerged in iced
Krebs buffer, and perfused by an aortic cannula delivering normothermic
(37°C) modified Krebs Henseleit solution containing (in mM) 118 NaCI, 5.9
KCI, 1.75 CaCI2, 1.2 mM MgS04, 0.5 EDTA, 25 NaHC03, 16.7 glucose at pH
7.4. The perfusate was gassed with 95% 0 2 - 5% C0 2 , which results in a p0 2
above 600 mmHg at the level of the aortic canula. All perfusions prior to
mitochondria and signalosome isolation were 50 min long. Drug perfusions
were comprised of 25 min stabilization, 15 min bradykinin (100 nM) or ouabain
(50 jJvl), and 10 min wash. Control perfusions were 50 min without
interruption.
To assess infarct size and functional recovery following drug treatments
and ischemia, seven groups of hearts were studied (n = 4-6 in each group).
Following stabilization and pretreatment, all groups were exposed to 25-min
zero-flow global ischemia followed by 120 min of reperfusion with standard
Krebs solution. The ischemia-reperfusion group (IR) was allowed to stabilize
under aerobic conditions for 40 min. Prior to ischemia, the ouabain- (Ouab)
and bradykinin- (BK) treated groups were allowed to stabilize under aerobic
conditions for 25 min, followed by 15 min perfusion with a buffer containing 50
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mM of ouabain, 100 nM bradykinin, or 5 |aM anisomycin, respectively. Where
used, 5HD (300 jiM) or SB203580 (1 jiM), were added to the perfusate 5 min
before ouabain, bradykinin or anisomycin, and included in the perfusate during
the subsequent 15 min perfusion with ouabain, bradykinin or anisomycin.
Following ischemia, the hearts in each group were reperfused for 120
min and infarct size was estimated by the method of Ytrehus, et al. (241). The
infarct staining protocol was as follows, 15 ml of 1% wt/vol
2,3,5-Triphenyltetrazolium chloride (TTC) in phosphate-buffered saline pH 7.4
at 37 °C was infused into the coronary circulation at a rate of 0.5 ml/gm/min.
The eluted stain from the cardiac veins was collected and recirculated. After
approximately 15 min of perfusion the epicardial surface was deep red. Hearts
were then removed from the cannula and fixed overnight in 10 % Formalin.
Hearts were removed from formalin, sectioned along the atrioventricular plane
into ~1mm sections. Sections were placed between two microscope slides
and computerized area analysis was performed using Scion image and the
infarct size of each heart was expressed as a fraction of the total area at risk.
Infarct size for each heart was determined by averaging the infarct area of the
5-6 cross-sections. The rate-pressure product (RPP) data shown if Fig. 5.7A
were calculated using the average RPP measured during the 15-min drug
treatment for each experimental condition. The experimental protocols
complied with the Guiding Principles in the Use and Care of Animals published
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by the National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Mitochondria Isolation
Mitochondria from rat hearts were isolated immediately following 50 min
Langendorff perfusions. Mitochondria from untreated assay rat hearts and
livers were isolated by differential centrifugation without previous perfusion, as
thoroughly described in chapter 2 (31). The resulting crude mitochondrial
fractions were further purified in a self-generated 24% Percoll gradient,
resulting in a purified mitochondrial fraction and a low-density fraction enriched
in caveolin and signaling molecules, which we have termed the light layer or
LL. Mitochondrial protein concentration was estimated using the Biuret
reaction (75).

Signalosome isolation - Purified LL (PLL)
The purification was exactly as that described in chapter 4 and in the nondetergent caveolae isolation protocol of Smart et al (207). Briefly, the LL
fraction was adjusted to 2 ml, mixed with 50% Optiprep in buffer A (250 mM
sucrose, 20 mM TRIS-CI (pH 7.8), 1 mM EDTA), and placed in the bottom of a
12 ml centrifuge tube. A 20-10% Optiprep gradient was layered on top, and
the tubes were centrifuged at 52,000xa; for 90 min. Following centrifugation,
the top 5 ml were collected and mixed with 4 ml of the 50% Optiprep solution.
This mixture was then overlayed with a 5% Optiprep solution and centrifuged
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again at 52,000xg for 90 min. The signalosome fraction was identified as an
opaque band at the 5% interface.
Matrix volume measurements
MitoKATP assays. MitoKATP activity is determined by monitoring changes in
mitochondrial light scattering, as previously described (16, 31, 35).
Mitochondria from untreated assay hearts were added at 0.1 mg/ml to medium
containing K+ salts of CI" (120 mM), HEPES pH 7.2 (10 mM), succinate (10
mM), and phosphate (5 mM) supplemented with MgCI2 (0.5 mM), 5 (aM
rotenone , 0.67 [iM oligomycin. LL or purified LL were added as indicated in
figures. Light scattering changes of 0.1 mg/ml mitochondrial suspensions
were followed at 520 nm and 25 °C and are reported as "Matrix Volume",
which is calculated based on inverse absorbance normalized for protein
concentration, Ps:
Matrix volume = Ps (1/A - 1/A^)
Data are summarized in bar graphs as "MitoKATP activity (%)", given by
100 x [V(x) - V(ATP)]/[V(0) - V(ATP)]
where V(x) is the observed steady-state volume at 120 s under the given
experimental condition and V(ATP) and V(0) are observed values in the
presence and absence of ATP, respectively. Statistical significance of the
difference of the means was assessed using unpaired Student's t-test. A
value of p < 0.05 was considered significant. It should be noted that mitoKATP134

dependent K+ flux has been validated by 5 independent measurements - light
scattering, direct measurements of K+ flux, H+ flux, respiration, and H202
production. Each of these was found to yield quantitatively identical measures
of K+ flux, using valinomycin-induced K+ flux as a calibrating control (32).
Mitochondrial Permeability Transition Pore (MPT) Assay
In vitro studies of MPT opening were carried out by light scattering (32).
Briefly, mitochondria (0.1 mg mitochondrial protein/ml) were incubated in the
assay medium described above at 30 °C (t=0), CaCI2 (100 |aM as free Ca2+)
was added at 20 s, ruthenium red (0.5 pM) was added at 40 s to block further
Ca2+ uptake, and CCCP was added at 60 s (250 nM), to synchronize MPT
opening (178). These experiments were performed in the absence of MPG or
catalase. The LL was added simultaneously with mitochondria. MPT data are
summarized in bar graphs as "MPT inhibition (%)", which was calculated by
taking Ca2+-induced swelling rates in the absence and presence of 1 jaM
cyclosporin A as 0% and 100%, respectively. Statistical significance of the
difference of the means was assessed using unpaired Student's t-test. A
value of p < 0.05 was considered significant.

Assay of mitoKATP-opening by Recombinant PKCs and Src
Recombinant PKCs (expressed in sf 21 insect cells) was purchased from US
Biologicals, and Recombinant c-Src p60 (expressed in sf9 insect cells) was
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purchased from Upstate Biochemical. The enzymes were incubated for 1 min
at 30°C in 40 nl_ of buffer containing 20 mM Tris (pH 7.5), 10 mM MgCI2, 25
mM MnCI2. Following the incubation, the enzymes were added to the
mitochondrial light scattering assay.
Immunoblot Analysis
Proteins were separated by SDS-PAGE using 10% acrylamide precast gels
(BioRad) and transferred to polyvinylidine difluoride membranes by semi-dry
transfer. Membranes were blocked with 5% nonfat dry milk in 20 mM Trisbuffered saline and 0.5% Tween-20 (TBS-T) and incubated with primary
antibody over night in 5% BSA-TBS-T. The membrane was then incubated for
one hour with the appropriate secondary antibody conjugated to horseradish
peroxidase in TBS-T. The membranes were exposed to autoradiograph films,
which were scanned.
Chemicals
Anisomycin, SB203580, KT5823 , PP2, protein phosphotase 2A (PP2A) and
protein tyrosine phosphotase B1 (PTPB1) were purchased from Calbiochem.
PKC isoform-specific peptides were synthesized by EZ Biolabs (Westfield,
IN), according to the published amino acid sequences (27). Antibodies against
Src were from Santa Cruz, for Caveolin-3 from ABR Affinity Bioreagents, for
the al-subunit of Na/K-ATPase from ABCam Inc, for PKCs from BD
Biosciences. Phospho-p38 MAPK (Thr 180/Tyr 182) and p38 MAPK were
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purchased from Cell Signaling. Precast gels (10%) were from BioRad and
PVDF membranes were from Millipore. Optiprep was purchased from AxisSchield PoC AS (Oslo, Norway). Recombinant p38 MAPK (expressed in E.
coli) and all other chemicals were from Sigma.

137

5.4 Results
The ouabain signalosome possesses caveolar properties
We hypothesize that ouabain interaction with the Na,K-ATPase initiates
assembly of a signaling platform in sarcolemmal caveolae. This signalosome
then buds off and moves to mitochondria, where it interacts with the
mitochondrial outer membrane (MOM). The protocol described in "Methods"
to isolate the ouabain signalosome exploits the low density of these
cholesterol-rich vesicles. As shown in Fig. 1, the physical properties of the
ouabain light layer (LL) are consistent with a previous study of signalosomes
from bradykinin-treated hearts (186). Similarly to our previous work and the
findings of Smart et al, we find that visualization and immunogold labeling of
the vesicular structures indicates multiple copies of caveolin-3, the marker for
cardiac caveolar structures (Fig. 5.1 A) (206). Figure 5.1 B contains a Western
blot analysis of the isolated signalosome probed with antibodies for the
Na+/K+-ATPase, PKCs, Src, and caveolin-3. The ouabain signalosome was
enriched in each of these proteins as compared to fractions obtained from
sham-perfused hearts. In further experiments not shown, we found that methyl(3-cyclodextrin, a cholesterol binding agent, abolished the ability of the ouabain
signalosome to induce mitoKATP opening when added to mitochondria from
untreated hearts, whereas the nonionic detergent Triton X-100 had no effect.
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Figure 5.1 The PLL is caveolar in nature and contains signaling
molecules (A) Immunogold labeling with anti-caveolin-3 indicates that the
isolated structures are caveolar in nature. Magnification = 67,000x (B)
Immunoblot analysis shows a clear enrichment of the a-1 subunit of the
N\K+-ATPase, PKCs, Src, and caveolin-3 in PLL from ouabain-treated
hearts vs a similar fraction isolated from sham-perfused hearts.
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Sensitivity to methyl-p-cyclodextrin and resistance to Triton X-100 are
characteristic properties of caveolar membrane microdomains (3). These
results are similar to those previously obtained with the bradykinin
signalosome (186) and they support the notion that the isolated ouabain
signalosome is caveolar in nature.

The ouabain LL opens mitoKATP and inhibits the mitochondrial
permeability transition (MPT)
The low-density signalosome fraction isolated from ouabain-treated
hearts, here called light-layer or LL, opens mitoKATP to the same extent as
diazoxide in isolated mitochondria (Fig. 5.2 A). The traces contained in Fig.
5.2A show that both the LL and the purified LL (PLL, described in Methods)
from ouabain-treated hearts are capable of reversing the ATP-inhibited state
of mitoKATP. LL from sham-perfused hearts ("sham LL") and the residual LL
("RLL"), which are the proteins remaining after PLL are isolated, are unable to
open mitoKATP. A summary of these results is contained in fig. 5.2 B.
MitoKATP opening induced by the ouabain LL was reversed by the
mitoKATP-blocker 5-hydroxydecanoate (5-HD), the PKCs inhibitor sV^, the
Src inhibitor PP2, and the MAPK inhibitor SB203580 ("SB"). The effects of
Src and PKCs inhibitors implies that a phosphorylation event was required for
the observed effect. In light of this, we tested the ability of the serine/threonine
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protein phosphatase 2A (PP2A), and the protein tyrosine phosphatase B1
(PTPB1), to inhibit the LL effect. Both phosphatases inhibited the activity of
the LL, suggesting that both a serine/threonine and a tyrosine phosphorylation
were important in this process (Fig. 5.2B). Finally, we show that the PKG
inhibitor KT5823 (KT), which blocks activity of the bradykinin signalosome
(186), did not inhibit the mitoKATP opening by the ouabain LL. This is in full
agreement with a prior study that showed that protein kinase G (PKG) was not
involved in ouabain cardioprotection (173).
We showed previously that physiological or pharmacological opening
of mitoKATP inhibits the mitochondrial permeability transition (MPT) (32). This
is caused by a mitoKATP-dependent increase in mitochondrial ROS
production and subsequent activation of a PKCs which is constitutively
expressed in mitochondria (32, 93). As shown in Fig. 5.2C, addition of the
ouabain LL to isolated mitochondria inhibited Ca2+-initiated MPT by about
60%, which is approximately the same as the inhibition observed with
diazoxide (32). MPT inhibition by the LL was prevented by the mitoKATP
blocker 5-HD and the Src kinase inhibitor PP2. MPT inhibition was also
prevented by the phosphatases PP2A and PTPB1. These results are in
accordance with those contained in Fig. 5.2 B.
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Figure 5.2 (A) LL and Purified L!_ from ouabain-treated hearts open
mitoKATP and inhibit MPT in isolated mitochondria. Mitochondrial matrix
volume is plotted versus time. Aliquots of LL ("LL", 10-15 Lig/ml), purified LL
("PLL", 0.5 ng/ml), and residual LL ("RLL", 10-15 ng/ml) were added to medium
one second after the mitochondria. ATP (0.2 mM) was present in each run.
Diazoxide, the mitoKATP opener, was used at 30 LIM, PP2, a Src inhibitor, was
added at 0.5 LIM. Also shown is the inability of the residual LL (RLL) or the shamperfused LL (Sham LL) to open mitoKATP. Traces are representative of at least 5
independent experiments. 7 separate traces are plotted in the figure, and some of
them are superimposed. (B) Shown is a summary of data with a series of
inhibitors tested, plotted as "% mitoKATP activity" as described in methods . Each
inhibitor was added to the assay medium with the LL. Concentrations tested
were 300 uM 5-hydroxydecanoate (5HD), 0.5 LIM sV1-2, 0.5 LIM KT5823 (KT), 0.5
LIM PP2, 10 U/mL PP2A, 1 pM SB203580 (SB), 11 U/mL PTPB1. * indicates that
data were significantly different from ATP alone, and £ indicates that ATP were
not significantly different than ATP alone (p < 0.05). (C) Inhibition of the
mitochondrial Permeability Transition (MPT) by the addition of the LL was
reversed by a similar panel of compounds as described above. * indicates that
data were significantly different than the ouabain LL alone (p < 0.05).
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Signalosomes from rat heart open mitoKATP in rat liver mitochondria
Signal transmission from plasma membrane to mitochondria is a
feature of most cell types. We investigated whether signalosomes from heart
would interact with liver mitochondria to open mitoKATP. The data in Fig. 3
show that they do. Both the ouabain LL (white bars) and the bradykinin LL
(gray bars) open mitoKATP in liver mitochondria, and they exhibit the same
differences in inhibition by PP2, KT5823 and the phosphatases PP2A and
PTPB1 that were observed in heart mitochondria. Thus, the signalosome
mechanism is a general phenomenon.

PKCs plays dual roles in mitoKATP opening induced by the ouabain
signalosome
We have previously shown that there is an endogenous mitochondrial
PKCs that mediates mitoKATP opening (32, 34, 93). It was necessary to
distinguish between the mitochondrial and signalosome PKCs, each of which
is presumably inhibited by the specific peptide inhibitor sV^. We achieved
this distinction by simple dilution, as demonstrated by the data in Fig. 4A. To
study the signalosome PKCs, we preincubated signalosomes with the same
concentration of s V ^ (0.5 jaM) that we found by dose-response to inactivate
PKCs in mitochondria. Incubation of the ouabain LL was carried out for 1 min
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at 30° C, and the LL aliquot was then diluted 150-fold to 3 nM in the assay
medium. In separate experiments, we verified that this concentration, which is
well below concentrations required to inhibit PKCs (32, 199), had no effect on
mitoKATP opening. In experiments not shown here, we that the ability of the
bradykinin signalosome to open mitoKATP is not affected by preincubation with
sV^, but is blocked if 0.5 ^M sVU2 is present in the assay medium, reflecting
inhibition of the mitochondrial, but not the signalosome PKCs. These results
are contained in Fig. 5.4A and show that the two PKCss are necessary here,
one in the ouabain signalosome and one within mitochondria associated with
mitoKATP.
Western blot analysis of the PLL and mitochondria confirmed the
presence of PKCs in both the ouabain PLL and mitochondria (Fig. 5.4B). The
PLL fraction is a highly purified membrane fraction that contains a total of 7-15
\ig of protein per heart, and 5 \xg protein was typically loaded on to the gels.
As shown, the PLL of ouabain hearts contained an enrichment of PKCs as
compared to sham perfusion. As we have shown before, heart mitochondrial
PKCs is a very low-abundance protein (93). and we therefore loaded the gel
with 50 |o,g protein in order to observe it. This produces a sharp band, as
shown in Fig. 5.4 B.
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Figure 5.3 Ouabain- and bradykinin-treated LL open mitoKATP in isolated
liver mitochondria. Both the bradykinin and ouabain open mitoKATP in liver,
but respond differently to inhibitors. The ouabain LL is not sensitive to the PKG
inhibitor, KT5823 (KT) or the tyrosine phosphatase PTPB1, but unlike the
bradykinin LL is sensitive to the Src inhibitor PP2. All concentrations were the
same as those describe in figure 5.2.
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Figure 5.4 Dual PKCcs are mediating mitoKATP-opening in this system.
(A) Shown is the assay to differentiate between the PKCs present in the
ouabain LL and the PKCs present in mitochondria. 0.5 j^M sV^, when used
in the assay medium with mitochondria and the LL will inhibit PKCs present in
both locations (4th bar, "assay"). To inhibit only the LL PKCs we incubated an
aloquot of the LL with 0.5 j^M s V ^ for 1 min at 30°C and diluted the aloquot
into 3 mL assay medium (5th bar, "incub."). This makes the effective
concentration of e\ZU2 in the medium 3 nM. As the final bar shows, 3 nM s V ^
is not a sufficient dose to inhibit the mitochondrial PKCs. (B) The immunoblots
show that PKCs is present in both the mitochondrial and PLL fractions, but that
it is very low abundance in mitochondria, therefore substantially more protein
must be loaded in order to observe it.
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Figure 5.5 Recombinant Src and PKCs open mitoKATP
50 ng recombinant PKCs (specific activity = 1865 Units/mg) and/or 6 units
Src were incubated at 30°C for 1 min. Neither kinase alone induced
mitoKATP-opening, but the combination did. This opening was sensitive to
300 uM 5HD and 1 j^M SB203580. * indicates that p < 0.05 vs. either kinase
alone.

Src + PKCe
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The terminal kinases of the ouabain signalosome are Src and PKCs
Signalosomes contain a number of enzymes, including the terminal
kinases that interact with the MOM. Thus, the terminal kinase of the bradykinin
signalosome is PKG (186). The physiological data in Fig. 5.2 indicate that
both PKCs and Src are required for mitoKATP opening by the ouabain
signalosome. To further test this hypothesis, we assayed the ability of
recombinant PKCs and Src to open mitoKATP in vitro. As can be seen in Fig.
5.5, the addition of either kinase alone (third and fourth bars) did not open
mitoKATP, but the combination (fifth bar) did. This opening was sensitive to
5HD as well as the MAPK inhibitor SB203580.

The role of p38 MAPK in ouabain-induced mitoKATP opening
The data in Fig. 5.5 imply that p38 MAPK is the target of Src and
PKCs. Since Src and PKCs are the terminal kinases, and since signalosome
function is blocked by the phosphatases PP2A and PTPB1 (Fig. 2B), p38
MAPK must be in the MOM. Indeed the immunoblot of Fig. 5.6 demonstrates
the presence p38 MAPK in Percoll-purified mitochondria. We also observe an
increase in phosphorylation of p38 MAPK (Thr 180/Tyr 182) after the heart has
been treated with ouabain. Thus, mitochondria contain p38 MAPK, and it is
acting as receptor for the ouabain signalosome that confers the signal to open
148

mitoKATP.
It has not previously been shown that p38 MAPK is involved in ouabain
cardioprotection. We now show, in the Langendorff perfused heart model, that
cardioprotection afforded by ouabain is blocked by SB203580, the inhibitor of
p38 MAPK (Figs. 5.7A and B). We also show that cardioprotection can be
induced by direct activation of p38 MAPK with anisomycin and that this
protection can be blocked by 5-HD. Finally, to emphasize the distinct
differences between the cardioprotective pathways triggered by ouabain and
bradykinin (173), we show that SB203580 did not block bradykinin
cardioprotection (Figs. 5.7A and B).

149

Figure 5.6 Mitochondria from ouabain-treated hearts shows
increased phosphorylation of p38 MAPK
50 j^g of Percoll purified mitochondria was loaded per lane and samples
were probed with anti-phosphorylated p38 MAPK (Thr 180/Tyr 182) and
anti-p38 MAPK. The positive control was 5 pig recombinant MAPK.
Mitochondria isolated from ouabain-treated hearts (ouab) showed enhanced
phosphorylation of p38 MAPK as compared to sham perfused hearts
(sham).
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Figure 5.7. Effects ofp38 MAPK inhibition on ouabain and
bradykinin cardioprotection. (A) Functional cardiac recovery expressed
as rate-pressure product (RPP). See "Materials and Methods" for details
on perfusion protocols. Ischemia-reperfusion (IR) is used as the standard
for cardiac damage. 50 fj,M ouabain (Ouab) or 5 |aM anisomycin afforded
cardioprotection, both were inhibited by 1 ^M of the p38 MAPK inhibitor
SB203580 (SB) and 300 |Jv1 5HD. The cardioprotective dose of
bradykinin, 100 nM, was not blocked by 1 JJ.M SB203580. (B) Infarct size
measurements, expressed as percent of area at risk, indicate that this
measure of cellular necrosis mirrors the functional cardiac recovery.
Individual hearts (o) and group means (•) with standard error bars are
shown. * indicates p < 0.05 vs. control IR.
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5.5 Discussion
The primary function of the N+,K+-ATPase is to transport ions across
the cell membrane; the signaling functions of N+,K+-ATPase have been more
recently described. For example, the N+,K+-ATPase is capable of modulating
its own gene expression and the expression of genes involved in cell growth
(150, 158). Ouabain binding to the N\K+-ATPase has been linked to
nonproliferative cell growth (hypertrophy) in the heart through the instigation of
signal transduction pathways that originate at the N+,K+-ATPase and promote
induction or repression of the transcription of several cardiac marker genes
known to be involved in the hypertrophic response (144, 234, 235). Ouabain
treatment has been shown to cause a rapid activation of Src family kinases
with associated recruitment and activation of phosphlipase Cy (144, 228).
The downstream activation of enzymes such as PKC and ERK has also been
observed (144, 180, 235, 242). The presence of multiple binding motifs that
foster protein-protein intereaction suggest the N+,K+-ATPase as a prime
candidate for receptor-mediated signal transduction (228). In fact, the N+,K+ATPase signalosome hypothesis was put forth by Xie and colleagues in 2003
(236).
The presence of the N+,K+-ATPase in caveolae strengthens the
signalosome hypothesis, 20-30% of the a1-subunit of Na,K-ATPase is
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normally located in caveolae (131). Caveolae are membrane microdomains
that sequester and regulate signaling molecules (127, 129). Caveolins
interact with cholesterol and signaling proteins including receptors, Src family
kinases, and adapter proteins. Recent studies have indicated that many of
these interactions are mediated through the binding of caveolin scaffolding
domains to caveolin-binding motifs of the target proteins. Based on sequence
analysis, two caveolin-binding motifs seem likely on the a 1 subunit of N+,K+ATPase (236). Significantly, ouabain appears to regulate the interaction of
caveolin-1 with the N+,K+-ATPase and induce the formation of the N\K+ATPase -Src-caveolin-1 complex. Ouabain also stimulates tyrosine
phosphorylation of caveolin-1 in LLC-PK1 cells, and caveolar p42/44 MAPKs
in cardiac myocytes (131, 228).
This study proposes that ouabain cardioprotection is mediated by a
signalosome mechanism. The cardioprotective signalsome hypothesis states
that binding of ouabain to its receptor, the N+,K+-ATPase, instigates the
formation of a caveolar signaling complex that mediates the opening of
mitoKATP and inhibition of celluar necrosis. This hypothesis is supported by
experiments that assay the composition and behavior of the isolated
signalosome from ouabain-treated hearts. The signalosome is a low-density
fraction enriched in caveolin-3, the a-subunit of N+,K+-ATPase, Src, and
PKCs. It is subfractionated from the mitochondrial fraction of treated hearts,
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and because it contains activated kinases, can be used to open mitoKATP in
isolated untreated mitochondria.
As shown in Figs. 5.2 and 5.3, the ouabain signalosome fraction (LL)
opened mitoKATP in untreated heart and liver and this effect was sensitive to
inhibitors of mitoKATP, Src, PKCs, and MAPK, but not PKG. This is in
agreement with a recent study that compared the cardioprotective profile of the
peptide bradykinin with that of ouabain. We found that although both pathways
required Src, mitoKATP, and ROS, only bradykinin utilized protein kinase G
(PKG) and guanylyl cyclase (173). Ouabain cardioprotection was not affected
by inhibitors of PKG or guanylyl cyclase. Studies in both the perfused heart
and isolated mitochondria have determined that PKG acts immediately
proximal to mitoKATP-opening in bradykinin-mediated pahtways (31, 161).
Most recently, in a study describing the signalosome hypothesis for bradykinin
cardioprotection, we found that the isolated signalosome fraction from
bradykinin-treated hearts contained activated PKG that mediated mitoKATPopening in vitro (186). The fact that PKG did not appear to be involved in
ouabain cardioprotection suggested that the upstream pathways must be
divergent and result in mitoKATP-opening via different terminal kinases .
It has been proposed that PKCs and Src coexist in signaling complexes
that mediate cardioprotection (181, 226). Our data agree with this; the
ouabain signalosome contains active Src and PKCs working in concert to

154

mediate mitoKATP-opening (figs 5.2, 5.3, and 5.4). It is of note that we propose
that three PKCss are acting in this system, one within the signalosome, and
two within mitochondria associated with mitoKATP and MPT. Our previous
work indicates that these PKCs play distinct roles in mitochondria modulating
both mitoKATP and MPT (34, 93, 186).
We also investigated the ability of the recombinant forms of PKCe and
Src to mimic the effects of the ouabain signalosome. As shown in Fig. 5.5,
neither recombinant kinase alone could instigate mitoKATP-opening, but
incubation with both opened mitoKATPl and this opening was sensitive to
SB203580, the p38 MAPK inhibitor. The ability of the recombinant enzymes
to mimic the mitoKATP-opening behavior of the ouabain signalosome suggests
that these are in fact the active elements of the ouabain signalosome. The
inhibition of the effect by SB203580 suggests that p38 MAPK must be present
in the outer membrane of mitochondria. Indeed, immuoblot analysis revealed
the presence of p38 MAPK in mitochondria and an increase in its
phosphorylated form following ouabain treatment (fig 5.6).
To establish the role of p38 MAPK in this system, we performed
cardioprotection experiments in the isolated perfused heart (fig. 7A and B).
We found that inhibition of p38 MAPK blocked ouabain cardioprotection, as
measured by both functional recovery and infarct size. Interestingly, bradykinin
cardioprotection was not blocked by SB203580, which further suggests a
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divergence of these two cardioprotective pathways. Anisomycin, the p38
MAPK activator, protected the heart, and this protection was blocked by the
mitoKATP blocker, 5HD.
Both the presence of p38 MAPK in mitochondria, and its action as the
receptor for the signalosome, suggest a new paradigm for the roie of this
enzyme in cardioprotection. There has been some controversy concerning the
role of p38 MAPK in cardioprotection, some studies have found its activation
to be cardioprotective, and alternately, other studies have found its inhibition to
be cardioprotective (137, 143, 151). The relative role of p38 MAPK in
preconditioning seems to be strongly contingent on the protocol, but it may
also be which receptor-mediated pathway has been activated. As can be
seen in figs. 7A and B, bradykinin cardioprotection was not blocked by
inhibition of p38 MAPK with SB203580, whereas ouabain was. It may be that
the role of p38 in cardioprotection is determined by its location and sequencial
activation (136, 196, 243). The addition of p38 MAPK to the mitochondrial
paradigm is novel. However, it has been demonstrated that PKCs and p38
MAPK co-localize with cardiac mitochondria and that this association
increases with over expression of PKCs (12). It has also been shown that
PKCs and Src modulate p38 MAPK following activation of muscarinic
receptors (149). How the signal is being transduced from p38 to mitochondrial
PKCs is of great interest and will certainly be the work of future studies.
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Overall, these data offer support to the signalosome hypothesis for
cardioprotection. As we have shown previously with bradykinin, we now show
with ouabain, that treating the heart with cardioprotective agents initiates the
formation of a signaling platform that can be isolated from mitochondria. The
signalosome contains the enzymes necessary to open mitoKATP. The fact that
the ligands induce activation of different enzymes (PKCs/Src or PKG)
suggests that although the mechanism is general, the pathways are unique. In
consideration of the highly specific nature of signaling cascades, it is not
surprising that the signalosome contains the enzymes specific to its receptoractivated pathway. Future work will investigate the mechanisms of
signalosome scaffolding and delivery, as well as further analyze the content
and physiology of these platforms.
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6. Conclusions and Future work
Recent years have brought robust advances in our understanding of
cardiac signal transduction during cardioprotection against ischemiareperfusion and particularly the pivotal role of mitochondria in these processes.
This study seeks to describe a novel paradigm for integration of the signaling
pathways that are instigated upon cardioprotective treatments, from activation
of sarcolemmal receptors to mitochondrial permeability transition. We
suggest that interaction of the cardioprotective ligand with its receptor induces
the formation of a signaling platform (which we have termed the signalosome)
that is scaffolded by caveolins and contains the activated enzymes of the
pathway. Upon interaction of the signalosome with mitochondria, the
intramitochondrial pathway is initiated, whereby PKCs activates mitoKATP,
increased K+ flux causes an increase in ROS production, and MPT is inhibited
via a second, ROS-activated PKCs.
This work, which explores the current understanding of the mechanistic
link between plasma membrane receptors and mitochondrial targets of
cardioprotection, also points to several areas that require further investigation.
This study does not address the mechanism that is utilized in delivery of the
signalsomes to mitochondria. It seems likely that the cytoskeleton would play a
crucial role here, and future studies would benefit from analyzing the roles
played by microtubles and microfilaments in scaffolding and transport. Also, if
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this is in fact a general phenomenon, then one would expect to find
signalosomes modulating many forms of receptor-mediated signaling.
Examinations of the nucleus and sarcoplasmic reticulum could be very
informative regarding signalosome-mediated changes in gene expression and
Ca2+ handling, respectively.
The intramitochondrial signaling hypothesis has provided a suitable
model within which to examine the pathways that are instigated by opening of
mitoKATP in vivo. There are still many aspects of this pathway that require
further analysis. Though this study in particular does examine the details of
these issues, it is interesting to speculate on the nature of these processes.
For example, ROS production instigated by matrix alkalinization is thought to
arise from complex I (5), and yet the mechanism of this production remains a
mystery. In fact, much debate remains regarding the specific site within
complex I that from which ROS arises (59). It is postulated that these ROS are
activating PKCs, but it is possible that activation occurs by one of the other
mechanisms known to activate PKCs such as binding to activating proteins or
diacylglycerol. As discussed in the Introduction of this study, activation of
PKCs is complex, and in light of the multiple PKCss postulated to be acting in
this system, it would be interesting to understand if these are being activated
by different mechanisms (193).
In summary, the work presented here investigates the interactions
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among cytosolic signaling components and mitochondria. It also examines the
intramitochondrial signaling pathways that are triggered by cellular events. A
mechanistic understanding of these pathways could lend powerful insight into
the decision between cell survival and cell death during an acute myocardial
infarction.
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